WO1998001417A1 - Composes actifs comme recepteurs du calcium - Google Patents
Composes actifs comme recepteurs du calcium Download PDFInfo
- Publication number
- WO1998001417A1 WO1998001417A1 PCT/JP1997/002358 JP9702358W WO9801417A1 WO 1998001417 A1 WO1998001417 A1 WO 1998001417A1 JP 9702358 W JP9702358 W JP 9702358W WO 9801417 A1 WO9801417 A1 WO 9801417A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- naphthyl
- halogen
- substituted
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 296
- 239000011575 calcium Substances 0.000 title claims abstract description 100
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract description 56
- 229910052791 calcium Inorganic materials 0.000 title abstract description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 370
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 106
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 48
- 239000001257 hydrogen Substances 0.000 claims abstract description 31
- 125000003118 aryl group Chemical group 0.000 claims abstract description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 24
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 13
- 239000001301 oxygen Substances 0.000 claims abstract description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract description 11
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 222
- 239000000203 mixture Substances 0.000 claims description 177
- 230000002829 reductive effect Effects 0.000 claims description 165
- 210000004027 cell Anatomy 0.000 claims description 125
- 229910052736 halogen Inorganic materials 0.000 claims description 112
- 150000002367 halogens Chemical class 0.000 claims description 105
- -1 Ariru Chemical class 0.000 claims description 94
- 230000000694 effects Effects 0.000 claims description 73
- 125000003545 alkoxy group Chemical group 0.000 claims description 68
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 64
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 58
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 claims description 52
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 claims description 52
- 102000005962 receptors Human genes 0.000 claims description 49
- 108020003175 receptors Proteins 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 42
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 39
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 39
- 230000000849 parathyroid Effects 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 36
- 230000028327 secretion Effects 0.000 claims description 36
- 125000003342 alkenyl group Chemical group 0.000 claims description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 25
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 25
- 150000001412 amines Chemical class 0.000 claims description 24
- 230000002159 abnormal effect Effects 0.000 claims description 21
- 125000001624 naphthyl group Chemical group 0.000 claims description 21
- 102100036893 Parathyroid hormone Human genes 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 19
- 239000000199 parathyroid hormone Substances 0.000 claims description 19
- 229960001319 parathyroid hormone Drugs 0.000 claims description 19
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 210000002997 osteoclast Anatomy 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 210000000988 bone and bone Anatomy 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 230000003834 intracellular effect Effects 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 201000002980 Hyperparathyroidism Diseases 0.000 claims description 8
- 208000001132 Osteoporosis Diseases 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 210000002510 keratinocyte Anatomy 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 7
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims description 7
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims description 7
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 230000000148 hypercalcaemia Effects 0.000 claims description 7
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 210000002993 trophoblast Anatomy 0.000 claims description 7
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 6
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical group C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 claims description 6
- 210000003904 glomerular cell Anatomy 0.000 claims description 6
- 210000005234 proximal tubule cell Anatomy 0.000 claims description 6
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 5
- 125000005152 trihalomethanesulfonyl group Chemical group 0.000 claims description 5
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 5
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 4
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 4
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 201000006409 renal osteodystrophy Diseases 0.000 claims description 4
- 229930192474 thiophene Chemical group 0.000 claims description 4
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 3
- 230000003169 placental effect Effects 0.000 claims description 3
- 125000004951 trihalomethoxy group Chemical group 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 229940125810 compound 20 Drugs 0.000 claims description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 6
- 239000001294 propane Substances 0.000 claims 6
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 5
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims 5
- 229940090012 bentyl Drugs 0.000 claims 4
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 3
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 3
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical group [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 claims 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 1
- XKXWYCOGOULEAN-LLVKDONJSA-N N'-[(1R)-1-naphthalen-1-ylethyl]propanehydrazide Chemical compound C(CC)(=O)NN[C@H](C)C1=CC=CC2=CC=CC=C12 XKXWYCOGOULEAN-LLVKDONJSA-N 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 102000013566 Plasminogen Human genes 0.000 claims 1
- 108010051456 Plasminogen Proteins 0.000 claims 1
- VHOCIKOQVGYQFQ-UHFFFAOYSA-N S1NCCCC2=C1C1=CC=CC=C1C=C2 Chemical compound S1NCCCC2=C1C1=CC=CC=C1C=C2 VHOCIKOQVGYQFQ-UHFFFAOYSA-N 0.000 claims 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims 1
- 239000004312 hexamethylene tetramine Substances 0.000 claims 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000005002 aryl methyl group Chemical group 0.000 abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 abstract description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 343
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 273
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 185
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 168
- 239000000243 solution Substances 0.000 description 163
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 144
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 124
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 118
- 230000015572 biosynthetic process Effects 0.000 description 114
- 238000003786 synthesis reaction Methods 0.000 description 114
- 239000002904 solvent Substances 0.000 description 111
- 239000000741 silica gel Substances 0.000 description 110
- 229910002027 silica gel Inorganic materials 0.000 description 110
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 104
- 238000004440 column chromatography Methods 0.000 description 88
- 229910000027 potassium carbonate Inorganic materials 0.000 description 82
- 239000010410 layer Substances 0.000 description 77
- 239000012230 colorless oil Substances 0.000 description 74
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 71
- 239000012044 organic layer Substances 0.000 description 69
- 229910052938 sodium sulfate Inorganic materials 0.000 description 61
- 235000011152 sodium sulphate Nutrition 0.000 description 61
- 238000000605 extraction Methods 0.000 description 54
- 238000010898 silica gel chromatography Methods 0.000 description 54
- 238000000926 separation method Methods 0.000 description 51
- 241000700159 Rattus Species 0.000 description 50
- 239000007788 liquid Substances 0.000 description 48
- 230000008859 change Effects 0.000 description 47
- 229910001410 inorganic ion Inorganic materials 0.000 description 47
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- 239000003921 oil Substances 0.000 description 45
- 235000019198 oils Nutrition 0.000 description 45
- 239000005416 organic matter Substances 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 229920006395 saturated elastomer Polymers 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- 238000005481 NMR spectroscopy Methods 0.000 description 34
- 239000013078 crystal Substances 0.000 description 32
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 31
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 28
- 238000005406 washing Methods 0.000 description 28
- 229940079593 drug Drugs 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- 238000000746 purification Methods 0.000 description 25
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- 238000003756 stirring Methods 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 238000001816 cooling Methods 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 208000035475 disorder Diseases 0.000 description 21
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical class O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 19
- 238000001035 drying Methods 0.000 description 19
- 239000006188 syrup Substances 0.000 description 19
- 235000020357 syrup Nutrition 0.000 description 19
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 17
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 17
- 229910052808 lithium carbonate Inorganic materials 0.000 description 17
- 238000010992 reflux Methods 0.000 description 17
- RTCUCQWIICFPOD-SECBINFHSA-N (1r)-1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C([C@H](N)C)=CC=CC2=C1 RTCUCQWIICFPOD-SECBINFHSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- CESGKXMBHGUQTB-VONOSFMSSA-N [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(OC(=O)CCCCCCCCCCCCC)C(C)(C)[C@H]3[C@@H]21 CESGKXMBHGUQTB-VONOSFMSSA-N 0.000 description 16
- 239000004744 fabric Substances 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 16
- 229910052799 carbon Inorganic materials 0.000 description 15
- 150000002500 ions Chemical class 0.000 description 15
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 14
- 239000012279 sodium borohydride Substances 0.000 description 14
- 229910000033 sodium borohydride Inorganic materials 0.000 description 14
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 13
- 150000002576 ketones Chemical class 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- KOAWAWHSMVKCON-UHFFFAOYSA-N 6-[difluoro-(6-pyridin-4-yl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]quinoline Chemical compound C=1C=C2N=CC=CC2=CC=1C(F)(F)C(N1N=2)=NN=C1C=CC=2C1=CC=NC=C1 KOAWAWHSMVKCON-UHFFFAOYSA-N 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 210000001685 thyroid gland Anatomy 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 10
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 9
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 9
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000003278 mimic effect Effects 0.000 description 9
- 229940075993 receptor modulator Drugs 0.000 description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 9
- 239000010936 titanium Substances 0.000 description 9
- 229910052719 titanium Inorganic materials 0.000 description 9
- 210000003771 C cell Anatomy 0.000 description 8
- 235000003332 Ilex aquifolium Nutrition 0.000 description 8
- 241000209027 Ilex aquifolium Species 0.000 description 8
- 230000002092 calcimimetic effect Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- HNGQQUDFJDROPY-UHFFFAOYSA-N 3-bromobenzenethiol Chemical compound SC1=CC=CC(Br)=C1 HNGQQUDFJDROPY-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 241000282887 Suidae Species 0.000 description 7
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 7
- 230000004094 calcium homeostasis Effects 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000000287 oocyte Anatomy 0.000 description 7
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 229940124530 sulfonamide Drugs 0.000 description 7
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 125000005296 thioaryloxy group Chemical group 0.000 description 6
- BXXWFOGWXLJPPA-UHFFFAOYSA-N 2,3-dibromobutane Chemical compound CC(Br)C(C)Br BXXWFOGWXLJPPA-UHFFFAOYSA-N 0.000 description 5
- YUQUNWNSQDULTI-UHFFFAOYSA-N 2-bromobenzenethiol Chemical compound SC1=CC=CC=C1Br YUQUNWNSQDULTI-UHFFFAOYSA-N 0.000 description 5
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 102000055006 Calcitonin Human genes 0.000 description 5
- 108060001064 Calcitonin Proteins 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 108010081690 Pertussis Toxin Proteins 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 230000001746 atrial effect Effects 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 5
- 229960004015 calcitonin Drugs 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 210000001428 peripheral nervous system Anatomy 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 4
- RTCUCQWIICFPOD-UHFFFAOYSA-N 1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C(C(N)C)=CC=CC2=C1 RTCUCQWIICFPOD-UHFFFAOYSA-N 0.000 description 4
- SCURCOWZQJIUGR-UHFFFAOYSA-N 3-(trifluoromethyl)benzenethiol Chemical compound FC(F)(F)C1=CC=CC(S)=C1 SCURCOWZQJIUGR-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 210000002406 gastrin-secreting cell Anatomy 0.000 description 4
- 230000001434 glomerular Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000005190 thiohydroxy group Chemical group 0.000 description 4
- CJWGCBRQAHCVHW-SSDOTTSWSA-N (1r)-1-(3-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC([C@@H](C)N)=C1 CJWGCBRQAHCVHW-SSDOTTSWSA-N 0.000 description 3
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 3
- XVGQHRKNXSUPEF-UHFFFAOYSA-N 2-(trifluoromethyl)benzenethiol Chemical compound FC(F)(F)C1=CC=CC=C1S XVGQHRKNXSUPEF-UHFFFAOYSA-N 0.000 description 3
- WCMLRSZJUIKVCW-UHFFFAOYSA-N 4-(trifluoromethyl)benzenethiol Chemical compound FC(F)(F)C1=CC=C(S)C=C1 WCMLRSZJUIKVCW-UHFFFAOYSA-N 0.000 description 3
- 241000013371 Amietia angolensis Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101100274581 Caenorhabditis elegans chc-1 gene Proteins 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 3
- 230000002763 arrhythmic effect Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical group [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 210000001842 enterocyte Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000019948 ion homeostasis Effects 0.000 description 3
- 210000004216 mammary stem cell Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 description 3
- DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 230000005070 ripening Effects 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LUZOFMGZMUZSSK-LRDDRELGSA-N (-)-indolactam V Chemical compound C1[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)C2=CC=CC3=C2C1=CN3 LUZOFMGZMUZSSK-LRDDRELGSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 2
- LVWSZGCVEZRFBT-UHFFFAOYSA-N 1,7-dibromoheptane Chemical compound BrCCCCCCCBr LVWSZGCVEZRFBT-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- ZDOIAPGLORMKTR-UHFFFAOYSA-N 2-Hydroxyfluorene Chemical compound C1=CC=C2C3=CC=C(O)C=C3CC2=C1 ZDOIAPGLORMKTR-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- HNJZDPKMMZXSKT-UHFFFAOYSA-N 3,4-dichlorobenzenethiol Chemical compound SC1=CC=C(Cl)C(Cl)=C1 HNJZDPKMMZXSKT-UHFFFAOYSA-N 0.000 description 2
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 2
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 2
- OKIHXNKYYGUVTE-UHFFFAOYSA-N 4-Fluorothiophenol Chemical compound FC1=CC=C(S)C=C1 OKIHXNKYYGUVTE-UHFFFAOYSA-N 0.000 description 2
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- IZSRJDGCGRAUAR-MROZADKFSA-M 5-dehydro-D-gluconate Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IZSRJDGCGRAUAR-MROZADKFSA-M 0.000 description 2
- IZSRJDGCGRAUAR-MROZADKFSA-N 5-dehydro-D-gluconic acid Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IZSRJDGCGRAUAR-MROZADKFSA-N 0.000 description 2
- GPZYYYGYCRFPBU-UHFFFAOYSA-N 6-Hydroxyflavone Chemical compound C=1C(=O)C2=CC(O)=CC=C2OC=1C1=CC=CC=C1 GPZYYYGYCRFPBU-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- LUZOFMGZMUZSSK-UHFFFAOYSA-N Indolactam-V Natural products C1C(CO)NC(=O)C(C(C)C)N(C)C2=CC=CC3=C2C1=CN3 LUZOFMGZMUZSSK-UHFFFAOYSA-N 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 210000005232 distal tubule cell Anatomy 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- AFMVESZOYKHDBJ-UHFFFAOYSA-N fluoren-9-ol Chemical compound C1=CC=C2C(O)C3=CC=CC=C3C2=C1 AFMVESZOYKHDBJ-UHFFFAOYSA-N 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 210000000050 mohair Anatomy 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- NWJUMMHVDMNYMJ-UHFFFAOYSA-N n-benzyl-1,1,1-trifluoromethanamine Chemical compound FC(F)(F)NCC1=CC=CC=C1 NWJUMMHVDMNYMJ-UHFFFAOYSA-N 0.000 description 2
- KDFFXYVOTKKBDI-UHFFFAOYSA-N n-ethylnaphthalen-1-amine Chemical compound C1=CC=C2C(NCC)=CC=CC2=C1 KDFFXYVOTKKBDI-UHFFFAOYSA-N 0.000 description 2
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 210000002990 parathyroid gland Anatomy 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229920001897 terpolymer Polymers 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- HYSOPXHRAHXSFM-UHFFFAOYSA-N (1-methylcyclohexa-2,4-dien-1-yl)methanamine Chemical compound NCC1(C)CC=CC=C1 HYSOPXHRAHXSFM-UHFFFAOYSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- SJUKJZSTBBSGHF-UHFFFAOYSA-N (2,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1Cl SJUKJZSTBBSGHF-UHFFFAOYSA-N 0.000 description 1
- VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- QBLPUSMNBSNAHZ-UHFFFAOYSA-N 1,1-dibromopentane Chemical compound CCCCC(Br)Br QBLPUSMNBSNAHZ-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- DKEGCUDAFWNSSO-UHFFFAOYSA-N 1,8-dibromooctane Chemical compound BrCCCCCCCCBr DKEGCUDAFWNSSO-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- FIFKRPFWLHBMHL-UHFFFAOYSA-N 1-(3-methoxyphenyl)-n-methylmethanamine Chemical compound CNCC1=CC=CC(OC)=C1 FIFKRPFWLHBMHL-UHFFFAOYSA-N 0.000 description 1
- CJWGCBRQAHCVHW-UHFFFAOYSA-N 1-(3-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC(C(C)N)=C1 CJWGCBRQAHCVHW-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QMSVNDSDEZTYAS-UHFFFAOYSA-N 1-bromo-1-chloroethane Chemical compound CC(Cl)Br QMSVNDSDEZTYAS-UHFFFAOYSA-N 0.000 description 1
- GNBRZRRANUHHGT-UHFFFAOYSA-N 1-phenylcyclohexa-2,4-dien-1-ol Chemical compound C=1C=CC=CC=1C1(O)CC=CC=C1 GNBRZRRANUHHGT-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- ZZLQHXCRRMUGQJ-UHFFFAOYSA-N 2'-Hydroxyflavone Natural products OC1=CC=CC=C1C1=CC(=O)C2=CC=CC=C2O1 ZZLQHXCRRMUGQJ-UHFFFAOYSA-N 0.000 description 1
- QIULLHZMZMGGFH-UHFFFAOYSA-N 2,5-dichlorobenzenethiol Chemical compound SC1=CC(Cl)=CC=C1Cl QIULLHZMZMGGFH-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- PXKSAXUKRMRORY-ZWKOTPCHSA-N 2-(3,4-dichlorophenyl)-n-[(1s,2r)-2-(2,5-dihydropyrrol-1-yl)cyclohexyl]-n-methylacetamide Chemical compound N1([C@@H]2CCCC[C@@H]2N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CC=CC1 PXKSAXUKRMRORY-ZWKOTPCHSA-N 0.000 description 1
- RFCQDOVPMUSZMN-UHFFFAOYSA-N 2-Naphthalenethiol Chemical compound C1=CC=CC2=CC(S)=CC=C21 RFCQDOVPMUSZMN-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- VXZBYIWNGKSFOJ-UHFFFAOYSA-N 2-[4-[5-(2,3-dihydro-1H-inden-2-ylamino)pyrazin-2-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC=1N=CC(=NC=1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 VXZBYIWNGKSFOJ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
- HGIDRHWWNZRUEP-UHFFFAOYSA-N 2-hydroxydibenzofuran Chemical compound C1=CC=C2C3=CC(O)=CC=C3OC2=C1 HGIDRHWWNZRUEP-UHFFFAOYSA-N 0.000 description 1
- FLFWJIBUZQARMD-UHFFFAOYSA-N 2-mercapto-1,3-benzoxazole Chemical compound C1=CC=C2OC(S)=NC2=C1 FLFWJIBUZQARMD-UHFFFAOYSA-N 0.000 description 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
- JKIFPWHZEZQCQA-UHFFFAOYSA-N 2-nitrobenzenethiol Chemical compound [O-][N+](=O)C1=CC=CC=C1S JKIFPWHZEZQCQA-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- NTIGNJOEVBTPJJ-UHFFFAOYSA-N 3,3-dibromopentane Chemical compound CCC(Br)(Br)CC NTIGNJOEVBTPJJ-UHFFFAOYSA-N 0.000 description 1
- MROVZCRMXJZHCN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxyethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCO)C=CC=1 MROVZCRMXJZHCN-UHFFFAOYSA-N 0.000 description 1
- ZMCQQCBOZIGNRV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(1,2,4-triazol-1-yl)ethyl]benzamide Chemical compound NCC1=CC(OC2=CC=CC(=C2)C(=O)NCCN2C=NC=N2)=NC(=C1)C(F)(F)F ZMCQQCBOZIGNRV-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- CQJDYPZUDYXHLM-UHFFFAOYSA-N 3-chlorobenzenethiol Chemical compound SC1=CC=CC(Cl)=C1 CQJDYPZUDYXHLM-UHFFFAOYSA-N 0.000 description 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- AXBVSRMHOPMXBA-UHFFFAOYSA-N 4-nitrothiophenol Chemical compound [O-][N+](=O)C1=CC=C(S)C=C1 AXBVSRMHOPMXBA-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-hydroxyindole Chemical compound OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- 101100389431 Caenorhabditis elegans enol-1 gene Proteins 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 102100035964 Gastrokine-2 Human genes 0.000 description 1
- 101710205776 Gastrokine-2 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000020161 Mineral related disease Diseases 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- ABDMQSFNJPYOLA-UHFFFAOYSA-N NS(=O)(=O)[N+]([O-])=O Chemical compound NS(=O)(=O)[N+]([O-])=O ABDMQSFNJPYOLA-UHFFFAOYSA-N 0.000 description 1
- 101000774651 Naja atra Zinc metalloproteinase-disintegrin-like kaouthiagin-like Proteins 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- RSXDHURAMASWBD-UHFFFAOYSA-N O=S(=O)N=C=S Chemical compound O=S(=O)N=C=S RSXDHURAMASWBD-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010031240 Osteodystrophy Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940123359 Potassium antagonist Drugs 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- BYWBCSRCPLBDFU-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)N BYWBCSRCPLBDFU-CYBMUJFWSA-N 0.000 description 1
- PRDBLLIPPDOICK-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1 PRDBLLIPPDOICK-UHFFFAOYSA-N 0.000 description 1
- USKGLOQFCMTSGG-UHFFFAOYSA-N [Na].[Na].[Na].[Ti] Chemical compound [Na].[Na].[Na].[Ti] USKGLOQFCMTSGG-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 150000001934 cyclohexanes Chemical class 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000001940 cyclopentanes Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 125000000950 dibromo group Chemical group Br* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000010222 extracellular calcium influx Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000004186 follicle cell Anatomy 0.000 description 1
- REHUGJYJIZPQAV-UHFFFAOYSA-N formaldehyde;methanol Chemical compound OC.O=C REHUGJYJIZPQAV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- GFAUNYMRSKVDJL-UHFFFAOYSA-N formyl chloride Chemical compound ClC=O GFAUNYMRSKVDJL-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 230000000121 hypercalcemic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004079 mineral homeostasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- VMFMUJZRXZXYAH-UHFFFAOYSA-N n-[5-[[5-chloro-4-[2-[2-(dimethylamino)-2-oxoacetyl]anilino]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound C=CC(=O)NC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)C(=O)C(=O)N(C)C)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C)CC1 VMFMUJZRXZXYAH-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- KRKUIQZXRHNRRY-UHFFFAOYSA-N n-methoxy-1-phenylethanamine Chemical compound CONC(C)C1=CC=CC=C1 KRKUIQZXRHNRRY-UHFFFAOYSA-N 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004862 thiobutyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 210000005233 tubule cell Anatomy 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/74—Sulfur atoms substituted by carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Definitions
- the present invention relates to the design, development, composition and use of novel molecules capable of modulating the activity of inorganic ion receptors, especially calcium receptors.
- extracellular calcium ions C a 2 -
- C a 2 - extracellular calcium ions
- ions such as: extracellular C a 2 - concentration (hereinafter, [C a-]) alters the functional response of these cells: one such specific cell is the parathyroid cells that secrete parathyroid hormone (parathyroid hormone, PTH).
- PTH is a key endocrine factor that regulates C a 2 -homeostasis in blood and extracellular fluid:
- PTH acts on bone and kidney cells to increase the concentration of C a 'in the blood: an increase in [C a 2 —] which in turn serves as a negative feedback signal that suppresses PTH secretion [C a 2 the mutual relationship between PTH secretion, and forms a mandatory mechanism to maintain the C a 2 one homeostasis of the body:
- Extracellular C a 2 acts directly on parathyroid cells and regulates PTH secretion [C a 2 ]. Sensitive changes have been identified in the parathyroid cell surface protein :, Brown et al , 366 Nature 574.1993: in parathyroid cells, this protein acts as a receptor one for extracellular C a + ( "the calcium receptor"), to sense a change in one 2 [C a, functional cellular response To initiate PTH secretion:
- extracellular C a 2 can be influenced to different cellular functions, thyroid parafollicular cells (C single cell) and parathyroid
- the role of extracellular Ca_2 + in cells is discussed in Nemeth, 11 CeU Calcium 323, 1990.These cells have been shown to express similar Ca2 + receptors Brown et al., 366 Nature 574, 1993;
- An object of the present invention is to provide a novel inorganic ion receptor monoactive compound having a structure different from the above-mentioned compounds.
- the present invention is preferably characterized by molecules capable of modulating one or more activities of an inorganic Ionreseata, this molecule was mimicked 3 ⁇ 4 influence of ⁇ ho 'to the extracellular C a 1 ⁇ calcium receptacle cover one
- the preferred use of such molecules is in the activity of inorganic ion receptor, preferably: to treat disease or disease by altering the activity of calcium receptor.
- the present invention provides the following formula:
- X is selected from the group consisting of oxygen, thio, sulfinyl, sulfonyl, carbonyl and amino:
- RR 2 , RRRR 6 , R 8 and R 9 are hydrogen, alkyl, cycloanolalkyl, alkenyl, alkynyl, trihalomethyl, aryl, -heteroaryl, heteroalicyclic, halogen, hydroxy, alkoxy, thioalkoxy, Aryloxy, Thioaryloxy, Carbonyl, Thiocarbonyl, C-Lupoxyl, 0-Carboxyl, C-Amide, N-Amide, O-Lumbamil, N-Lumbamil, O-Lumbamil, N- Independently selected from the group consisting of thiocarbamyl, cyano, nitro, amino and NR 1 ° R ! 1 , where:
- [ ⁇ '. Pee! ⁇ ! Is a force independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, carbonyl, torino, roacetyl, sulfonyl, and trihalomethanesulfonyl, or at least one nitrogen A 5- or 6-membered heteroalicyclic ring containing
- R groups may be taken together to form a fused 5- or 6-membered cycloalkyl group:
- R 7 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, halogen, cyano, hydroxy, alkoxy, O-carboxyl, rihaloacetyl and trihalomethanesulfonyl;
- a r 2 is selected from the group consisting of aryl and heteroaryl:
- p is an integer from 0-6;
- q is an integer from 0 to 14]
- a compound having the formula: F Provide salt or hydrate
- aryl refers to an all-carbon monocyclic or polycyclic fused ring (i.e., adjacent carbon atoms) having one or more rings having a fully conjugated pi-electron system. Represents a group which shares a pair of W 98/01 17
- groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, and indanyl; aryl groups which may be substituted or unsubstituted If present, the substituents may be halogen, trimethylamino, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, cyano.
- heteroaryl group is a ring having one or more atoms selected from the group consisting of nitrogen, oxygen and zeolite, and at least one ring is complete; this conjugated pi-electron system
- heteroaryl groups that represent monocyclic or fused ring (ie, rings that share adjacent pairs of atoms) groups include: hirolol, furan, dibenzofuran, carbazole, acridine, thiophene, Imidazole, benzimidazole, oxazole, thiazole, phenothiazine,, lyazole, thiadiazol, hirazol, benzoxazole, benzthiazole, indole, benzofuran, indazole, hillidine, hillimidine, quinolin , Isoquinoline, quinazoline, furin, phthalazine and furan Heteroaryl groups may be, but are not limited to, substituted.
- the substituents are preferably alkyl, cycloalkyl, halogen, tri /, lomethyl, Droxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, nitro, carbonyl, thiocarbonyl-sulfonamide, C-carboxy, ⁇ -carboxy, sulfy Nil, Snorre Ninore, O-Carmeno Mole, N-Carno Mole, O-Chocanole / Mole, N-Carbamyl, C-Amide, N-Amide, S-Sulfonamide, N- sulfo N'ami de, selected from Bok rehabilitation b methanesulfonic Ami de, amino and NK ''R 1' (two child R Oyobi! ⁇ 1 'are as defined previously herein) 1 1 3 ⁇ 4 is more than a group
- alkyl '' refers to a saturated aliphatic hydrocarbon, including straight-chain and branched-chain groups.
- an alkyl group has from 11 to 20 carbon atoms. ., More preferably, this is a medium sized alkyl having 1-10 carbon atoms. Most preferably, it is a lower alkyl having 1 to 4 carbon atoms ..,
- the alkyl group may be substituted or unsubstituted. When substituted, the substituent is preferably cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryl.
- a “cycloalkyl” group refers to an all-carbon monocyclic or fused-ring group (ie, a ring sharing a pair of adjacent carbon atoms) in which none of the rings has a fully conjugated pi- electron system.
- Examples of cycloalkyl groups that may be represented include, but are not limited to, cyclofurohan, cyclobutane, cyclo'pentane, cyclohentene, cyclohexane, cyclohexadiene, cycloheptane, and cycloheptane triene.
- Alkyl groups are substituted, unsubstituted, good When substituted, the substituent is preferably alkyl, aryl, heteroaryl, heteroaliphatic, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, cyano, halogen, carbonyl, carbonyl, Chocanoleboninole, C-force oleboxy, O-carboxy, ⁇ -force Luba 'mill, N-force / Leva mill, C-amide, N-amide, S-sulfonamide, N-sulfonamide, nitro, amino And NR : one or more groups independently selected from ⁇ R ''(where R 1, and ⁇ ⁇ 1 as defined herein above)-.
- alkenyl refers to an “lower alkenyl” group that represents an alkyl group, as defined herein, that is composed of at least two carbon atoms and at least one carbon-carbon double bond. Represents a lower alkyl group containing two double bonds:
- a “cycloalkenyl” group refers to a cycloalkyl group that contains one or more double bonds in ⁇ , and the double bond is completely conjugated in ⁇ ; does not form an electronic system.
- alkynyl refers to an alkyl group as defined herein that consists of at least two carbon atoms and at least one carbon-carbon triple bond.
- a “lower alkyl” group refers to at least one Represents a lower alkyl group containing a triple bond.
- Heteroaliphatic group means a monocyclic or fused group having one or more atoms selected from the group consisting of nitrogen, oxygen and iodide in the ring. Any ring completely conjugated with more than one double bond 7: Heteroalicyclic having no electron system 3 ⁇ 4 may be substituted or unsubstituted If it is, the substitution S is preferably: alkyl, cycloalkyl / realkyl, logen, tri /, methhydroxy, alkoxy, aryloxy, thiohydroxyl, thioalkoxy, thioallyloxy, cyano, Nitro, Carbonyl, thiocarbonyl, C-carboxy, o-carboxy, ⁇ one-piece ruby, N'-part, minore, O-part, phenol, sulfiel, sulfonyl, S-sulfonamide, N-sulfonamide, C-amid:, N-amide, amino and NK 1 ⁇ R 1: (
- Phenyl refers to a 6-membered aryl group
- a “benzyl” group refers to a phenyl-C 2 — group
- alkoxy group refers to both a 1-alkyl group and a 1-cycloalkyl group, as defined herein, and preferably the alkoxy group represents me, xy, or rihalmethoxy.
- a “trihalomethoxy” group refers to a Y 3 CO— group, where Y is as defined herein, and preferably Y is fluorine.
- Benzyloxy represents a benzyl-O— group.
- aryloxy is defined as an O-aryl group and an aryl group as defined herein.
- a “thioalkoxy” group refers to both a 1 S-alkyl group and a 1 S-cycloalkyl group as defined herein:
- a ⁇ thioaryloxy '' group refers to both a 1-S-aryl and a 1-S-teraryl group as defined herein.
- Halole minole means a carbonyl group even if I “is hydrogen
- the acetyl group j represents a carbonyl group which is 1 : 1: 1
- a ⁇ trihalomethyl '' group refers to a CY : t group (where Y is a halo group, preferably Y is fluorine).
- acetoxy refers to an o-carboxyl group where is Ci:
- Amino refers to — NR 1 ° R 11 groups, where R 1 “and R ′ ⁇ ′ are as defined herein.
- the "two-Toro" group represents one group:.
- the cyano group represents one C ⁇ N group
- a ⁇ methylenedioxy '' group refers to a 1-CH20- group in which two oxygens are covalently bonded to adjacent carbon atoms of an aryl or heteroaryl group.
- R 5 is Selected from the group consisting of hydrogen, unsubstituted lower alkyl and lower alkyl substituted with one or more halogens, wherein RR 2 , RR, R ' 3 and R : are hydrogen, R s and' R & Is hydrogen, unsubstituted alkyl, lower alkyl substituted with one or more halogen, unsubstituted alkenyl, lower alkenyl substituted with one or more halogen, unsubstituted alkynyl, substituted with one or more halogen
- a r which is independently selected from the group consisting of lower alkynyl, or which is joined together or is cycloalkyl or cycloalkenyl, Phenyl, naphthy
- ⁇ ⁇ r is an unsubstituted lower alkyl, Is phenyl substituted with one or more groups selected from the group consisting of halogen, trihalomethyl, unsubstituted lower alkoxy, trino, rometoxy,, rihaloacetyl and nitro, and ⁇ ⁇ is Selected from the group consisting of optionally substituted phenyl or optionally substituted naphthyl, particularly preferably Ar 2 is 3-methoxyphenyl or unsubstituted naphthyl.
- R a is methyl
- X is oxygen or: “tio”
- s is an integer from 0—14:
- Q is selected from the group consisting of oxygen, thio, carbonyl and mono-NH—;
- R 13 is hydrogen or lower alkyl:
- R 14 and R 15 are independently selected from the group consisting of hydrogen and alkyl, or taken together are cycloalkyl or cycloalkenyl.
- Ar 3 is an unsubstituted lower alkyl, a lower alkyl substituted with one or more halogens, a halogen, an unsubstituted lower alkoxy, a lower alkoxy substituted with one or more halogens.
- the present invention has the formula:
- Ar 6 is unsubstituted lower alkyl, lower alkyl substituted with one or more halogen, unsubstituted lower alkenyl, lower alkenyl substituted with one or more halogen, unsubstituted lower alkoxy, 1 or Lower alkoxy substituted with halogen, halogen, hydroxy, unsubstituted lower thioalkoxy, lower thioalkoxy substituted with one or more halogen, benzyloxy, methylenedioxy, ethylenedioxy, acetoxy, and one OCH.
- t 0 or 1:
- u is an integer from 0—1 1:
- w is selected from the group consisting of oxygen, zodiac, sulfiel, sulfonyl, carbonyl, and aminoka;
- R 16 and R 17 are H or unsubstituted lower alkyl
- R '8 is unsubstituted lower alkyl: i
- Ar 5 represents unsubstituted lower alkyl, halogen, unsubstituted lower alkoxy, lower alkyl substituted with one or more halogens, lower alkoxy substituted with one or more halogens.
- Carbazole pyridine, fluorene, quinoline, naphthalene, chromenone, tetrahydrobenzothiazebine, dibenzylamino, benzyl (naphthylmethyl) amino, benzyl (pyridylmethyl) a Mino, chenylmethyl (benzyl) amino, furylmethyl (benzyl) amino or N-alkyl-pyrrolylmethyl (benzyl) amino, ⁇ 6 is unsubstituted lower alkyl, halogen, unsubstituted lower alkoxy, 1 or Independently selected from the group consisting of lower alkyl substituted with halogen, lower alkoxy substituted with one or more halogen, hydroxy, and benzyloxy optionally substituted with halogen or methyl Or thiophene, furan, pyrrole, phenyl, naphthalene, pyridine, virazine or thiazol, which is optionally substituted with
- Ar 5 is unsubstituted lower alkyl, halogen, unsubstituted lower alkoxy, lower alkyl substituted with one or more halogens and lower alkoxy substituted with one or more halogens.
- 1 or is independently selected from the group consisting more which may be optionally substituted with groups Jibenjiruamino, benzyl (naphthylmethyl) a Amino or base Njiru (pyridylmethyl) Amino, a r 5 is naphthyl or More preferably 3 is methoxyphenyl, Ar 5 is dibenzylamino optionally substituted with unsubstituted alkyl, and Ar 5 is ⁇ -naphthyl: preferably of formula (1), (2) Or, the compound of the present invention represented by (3) is an R-enantiomer.
- the invention further off of the compounds of the invention described above: providing a mouth Drugs:
- the present invention by using the compounds described herein, provides a method of modulating the activity of calcium receptacle Puta: the compounds of the present invention, preferably, C a 'receptor (including ⁇ ) mimic the effects of C a 2 in one and inter - it (calcimimetic modulating) or C a 2 - proc effects C a "Okero receptor Slow
- the present invention also relates to the use of one or more inorganic ions or other
- a novel method for treating diseases characterized by abnormal concentrations of physical biochemicals, which are controlled by the activity of one or more calcium receptors, is proposed in particular:
- Treatment with the compound being administered may include one or more cells (eg, parathyroid cells, osteoclasts, pararenal glomerular cells, proximal tubule cells, keratinocytes), parathyroid follicle cells and placental nutrition
- abnormal condition is characterized by a level of the attribute that is statistically different from the level of the attribute observed in patients who do not suffer from the particular disease—ie, for example, in terms of inorganic protein concentrations "Anomalous: and! Indicates that the concentration of the ion in question is perceived by the medical community to be outside the normal range of such ion concentrations in healthy patients:
- the terms “treat,” “treating,” and “treatment” refer to reducing a disease or disorder and / or one or more symptoms, and preferably all symptoms, associated therewith. And / or removing and / or having a prophylactic effect against it.
- the invention comprises administering to a patient a therapeutically effective amount of a compound of the invention.
- Secondary hyperparathyroidism primary and secondary hyperparathyroidism
- renal osteodystrophy hypercalcemia with malignancy
- osteoporosis pageet's disease
- the term ⁇ administration '' refers to a method of introducing a compound of the invention in vivo or in vivo.
- the compounds and methods described herein may study the importance of the activity of inorganic ion receptors and prevent or treat related diseases and disorders. Can be maintained or propagated in a cell culture array.In a second sense, it may affect the inorganic ion receptor activity of a particular compound before attempting to use it in complex multicellular organisms such as humans. Determine the compound's IC 5 () or EC 5 (), preferably (as defined below)
- IC 5 () or EC 5 () preferably (as defined below)
- Carrier technologies include, but are not limited to:
- the invention features a method of modulating one or more activities of an inorganic ion receptor using a compound disclosed herein.
- the inorganic ion receptor is a Ca 2 receptor.
- the compounds of the present invention are capable of mimicking (including enhancing) or blocking the effect of extracellular Ca 2 on calcium receptor, such
- a preferred use of the novel compounds is in treating selected diseases by modulating inorganic ion receptor activity:
- the compounds of the present invention can be used to modulate the indicated diseases by modulating Ca 2 receptor activity. Can be used to treat.
- the present invention also includes a compound of the present invention described above, a C a 2, provides a composition for modulating the interaction between C a L receptions ter cell: present invention is further described above the present invention
- a patient having a disease that is characterized by abnormal levels of ions or substances controlled by the activity of the Ca 2 receptor, or a parathyroid cell, osteoclast, pararenal glomerular cell provides a composition for treating a patient having a proximal tubule cells, keratinocytes, two unusual [C a two or [C a in the thyroid parafollicular cells or placental trophoblast cells, characterized by the disease I do.
- the present invention relates to a primary and secondary hyperparathyroidism (primary and secondary hyperparathyroidism), Xu Providing a pharmaceutical composition for treating osteodystrophy, hypercalcemia, and osteoporosis
- Extracellular C a 1 is under strict homeostatic control blood clotting, nerve and muscle excitement possibilities, and various and inter - controlling Arosesu calcium receptacle porcine one protein of normal bone formation or the like, allo species specific Cells respond to changes in extracellular C a '-' concentration
- extracellular Ca ⁇ inhibits parathyroid hormone secretion from parathyroid cells, inhibits bone resorption by osteoclasts, and stimulates calcitonin secretion from C cells: ,
- Compounds that modulate inorganic ion receptor activity can be used to treat one or more activities of the inorganic ion receptor to treat a disease or disorder and have a beneficial effect on a patient: for example, osteoporosis It is an age-related disease characterized by low bone mass and increased risk of fracture: bone resorption by osteoclasts, directly (eg, * ⁇ bone marrow ion mimetic compounds) or endogenous Blockade indirectly by increasing the level of calcitonin (eg, a C-cell mimetic compound), and by decreasing the level of thyroid or parathyroid hormone (eg, a parathyroid cell ion-mimetic compound). Compounds can slow bone loss and thus have a beneficial effect on patients with osteoporosis,
- ⁇ ⁇ ⁇ is known to have anabolic effects on bone mass and proper bone remodeling, thus compounds that cause a transient increase in parathyroid hormone And dosing regimens (e.g., intermittent administration of parathyroid cell ion antagonists (i i ⁇ 1 ytic)) can increase bone mass in patients with osteoporosis.
- diseases or disorders characterized by a deficiency in one or more inorganic ion receptor activities can be treated according to the present invention.
- some forms of primary hyperparathyroidism have abnormally high levels.
- Calcium receptor modulators characterized by the small responsiveness of the parathyroid glands to parathyroid hormone and circulating calcium, can modulate the responsiveness of the parathyroid cells to calcium :
- the compound modulates calcium receptor activity, and is used in the treatment of a disease or disorder that is affected by modulating one or more activities of calcium receptor pig, preferably a disease or disorder.
- a disease or disorder Is characterized by abnormal bone and mineral homeostasis, more preferably by calcium homeostasis.
- Abnormal calcium homeostasis is characterized by one or more of the following activities: (1) blood ⁇ Abnormal increase or decrease of calcium: ('2) Urinary excretion of calcium (3) abnormal increase or decrease in bone calcium levels, eg, as measured by bone mineral density measurements: (4) abnormal absorption of dietary calcium: and (5) calcium homeostasis.
- molecules that modulate the activity of inorganic ion receptors are useful in the treatment of diseases characterized by abnormal inorganic ion homeostasis: preferably, this molecule is one of the inorganic ion receptors.
- Modulators of the apoptosis receptor include ion mimetics (ionmimetics), ion antagonists (i () niytics), calcium mimetics (ca1 cimimetics) and calcium antagonists ( ca 1 ci 1-tics) include: Ion mimetics are those that mimic the effects of increasing ion concentration on inorganic ion receiving pigs !:
- this molecule is one or more of: Affects more than one calcium receptor activity:
- a calcimimetic may have one or more Mimetic and preferably binds to calcium receptor
- Ion antagonists are caused by inorganic ions at the inorganic ion receptor. This molecule inhibits one or more calcium receptor activities: Potassium antagonists are evoked by extracellular calcium or more. It is an ion antagonist that inhibits calcium receptor activity and preferably binds calcium receptor.
- An inorganic ion receptor modulator can be formulated as a drug or composition and administered to a patient.
- the drug or composition can be a drug or composition that is in a form suitable for administration to a mammal, preferably a human.
- suitable forms for administration are known in the art and include toxicological effects, solubility, routes of administration and retention of activity.
- Another aspect of the invention features a method of treating a disease or disorder by modulating inorganic ion-receptor activity using the agents disclosed herein.
- Patients can be identified by standard medical techniques, such as routine blood analysis: (in order to detect protein deficiencies whose production or secretion is affected by changes in inorganic phosphorus levels) Aberrant levels of inorganic proteins affecting mineral ion homeostasis: by detecting proteins or hormones,
- the method of treatment comprises administering to the patient a therapeutically effective amount of an inorganic ion receptor modulator: a preferred embodiment: wherein the method comprises treating a disease or disorder characterized by abnormal inorganic ion homeostasis. And more preferably used to treat diseases or disorders characterized by abnormal calcium homeostasis.
- - Diseases or disorders characterized by abnormal power Lucid homeostasis include hyperparathyroidism, osteoporosis And renal osteodystrophy and other bone and mineral related disorders, and similar disorders (such as those described in standard medical textbooks such as "Harrison's Principles of Internal Medicine") are such diseases and diseases, mimic or block one or more of the effects of C a 2, protein in the body of the patient by the fact Or treated with calcium receptacle ⁇ terpolymer modifier on directly or indirectly affect the levels of other molecules,
- a “therapeutically effective amount” is one or more physical properties associated with or responsible for, or alleviated by, one or more symptoms of a disease or disorder in a patient. Or the amount of drug that partially or completely restores the biological harameter to normal>
- the patient has one or more of: a disease or disorder characterized by abnormal levels of calcium receptor regulatory components, and wherein the two molecules are parathyroid cells, osteoclasts.
- Cells pararenal glomeruli-cells, proximal tubule cells, distal tubule cells, central nervous system cells, peripheral nervous system cells, thick ascending limb of Henle's loop and cells of the collecting duct, epidermis Keratinocytes in the thyroid, parasites in the thyroid gland flS cells (C cells), enterocytes, trophoblasts in the placenta, platelets, vascular smooth muscle cells, atrial cells, gastrin secreting cells, glucanin secreting cells, kidney thread Stromal cells, mammary cells, beta The activity of cells selected from the group consisting of cells, fat cells, immune cells and gastrointestinal tract cells
- the cell is a parathyroid cell and the molecule reduces the level of parathyroid hormone in the patient's serum, even more preferably, the level is reduced to an extent sufficient to cause a decrease in plasma C a. And most preferably, parathyroid hormone levels are reduced to levels present in normal individuals ..:
- the present invention features agents and methods useful for treating diseases and disorders by modulating inorganic ion receptor activity.
- the molecules of the present invention provide extracellular calcium Detect and respond to changes and target different types of cellular calcium receptors-for example, secretion of parathyroid hormone from parathyroid glands using molecules that mimic extracellular forces Can selectively inhibit or osteoclasts; inhibit bone resorption by these cells or stimulate the secretion of lucitonin from C cells: such molecules are characterized by abnormal calcium homeostasis It can be used for the treatment of associated diseases or disorders such as hyperparathyroidism, renal osteodystrophy and osteoporosis.
- FIG. 1 shows the structure of the compound of the present invention synthesized in Examples 1-2: 3.
- FIG. 2 shows the synthetic scheme of the compound of the present invention wherein X is O in the formula (1).
- 1 shows a synthesis scheme of a compound of the present invention in which X is S in the formula (1).
- FIG. 4 shows a synthesis scheme of the compound of the present invention in which Ar; in the formula (1) is benzothiazole or benzoxazole.
- FIG. 5 shows the structures and synthesis schemes of the compounds of the present invention synthesized in Examples 24-24.
- FIG. 6 shows the structure and synthesis scheme of the compound of the present invention synthesized in Example 27-7
- FIG. 7 shows the structure and synthesis scheme of the compound of the present invention synthesized in Example :: 536.
- FIG. 8 shows the structures and synthesis schemes of the compounds of the present invention synthesized in Examples 37 to 4 ().
- FIG. 9 shows the structure and synthesis scheme of the compounds of the present invention synthesized in Examples 41 and 42.
- FIG. 10 shows the structures of the compounds of the invention synthesized in Examples 43-56:
- FIG. 11 shows the structures of the compounds of the invention synthesized in Examples 57-70.
- FIG. 12 shows the structure of the compound of the present invention synthesized in Examples 71 to 84:
- FIG. 13 shows the structure of the compound of the present invention synthesized in Examples 85 and 86.
- FIG. 14 shows the structure and synthetic scheme of the compound of the present invention synthesized in Example 88.
- FIG. 15 shows the structures of the compounds of the present invention synthesized in Examples 89 and 90.
- FIG. 16 shows the structures and synthetic schemes of the compounds of the present invention synthesized in Examples 91 to 93.
- FIG. 17 shows the structures and synthetic schemes of the compounds of the present invention synthesized in Examples 94-96:
- FIG. 18 shows the structure of the compound of the present invention synthesized in Examples 97 to 100 and the synthesis scheme.
- FIG. 19 shows the structure and synthetic scheme of the compounds of the present invention synthesized in Examples 101 to 103:
- FIG. 20 shows the structure and synthesis scheme of the compound of the present invention synthesized in Examples 104 to 1 () 6.
- FIG. 2 shows the structure and synthesis scheme of the compound of the present invention synthesized in Examples 107 to 109—
- FIG. 22 shows the structure and synthesis scheme of the compound of the present invention synthesized in Examples 110 to 112.
- FIG. 23 shows the structure and the synthesis scheme of the compound of the present invention synthesized in Examples 113 to 115.
- FIG. 24 shows the structures and synthetic schemes of the compounds of the present invention synthesized in Examples L16-118:
- FIG. 25 shows the structure and synthetic scheme of the compounds of the present invention synthesized in Examples 119-121:
- FIG. 26 shows the structure of the compound of the present invention synthesized in Examples 122-134:
- FIG. 27 shows the structure of the compound of the present invention synthesized in Example 1:35 to 147.
- FIG. 28 shows the structure of the compounds of the invention synthesized in Examples 148 to 189:
- FIG. 29 shows the structure of the compounds of the present invention synthesized in Examples 190-231:
- FIG. 30 shows the structure of the compounds of the present invention synthesized in Examples 23-22-271:
- FIG. 31 shows the structure of the compound of the present invention synthesized in Examples 272-231:
- FIG. 32 shows the structures of the compounds of the present invention synthesized in Examples 31 4 to 35 55:
- FIG. 33 shows the structure of the compound of the present invention synthesized in Examples 3556 to 3887.
- FIG. 34 shows the structures of the compounds of the present invention synthesized in Examples 388-407.
- FIG. 35 shows the structure of the compound of the present invention synthesized in Examples 408 to 4 L 3
- Figure: ⁇ 6 shows the structure of the compound of the present invention synthesized in Examples 4 16 to 4 28
- FIG. 7 shows the structure of the compound of the present invention synthesized in Examples 4 229 to 4 41.
- FIG. 3 ⁇ shows the structures of the compounds of the present invention synthesized in Examples 44 to 45. Show:
- FIG. 39 shows the structure of the compounds of the present invention synthesized in Examples 456-469.
- FIG. 40 shows the structure of the compounds of the present invention synthesized in Examples 470-480:
- FIG. 41 shows a structure of the compound of the present invention synthesized in Examples 48 1 to 49 ().
- FIG. 42 shows the structure of the compounds of the present invention synthesized in Examples 491-1495:
- FIG. 43 shows the structure of the compound of the present invention synthesized in Examples 496-504.
- FIG. 44 shows the structures of the compounds of the present invention synthesized in Examples 505-5177:
- FIG. 45 shows the structures of the compounds of the present invention synthesized in Examples 518 to 529:
- FIG. 46 shows the changes in plasma Ca 'levels of rats receiving compound 201 of the present invention:
- FIG. 47 shows the changes in plasma Ca levels of rats administered the compound K-252 of the present invention:
- FIG. 48 shows the change in plasma Ca ′ 2 — level of the rat to which the compound K—2076 of the present invention was administered.
- FIG. 49 shows the change in plasma Ca ′ level of rats to which the compound K-208 of the present invention was administered.
- FIG. 50 shows changes in plasma Ca-level of rats to which the compound K-212 of the present invention was administered.
- Figure 5 I shows the latch changes in plasma C a 2 'levels of Bok dosed with Compound K one 2 2 4 0 of the present invention
- FIG. 52 shows the change in the plasma Ca level of the rat to which the compound K-I'224 of the present invention was administered.
- FIG. 53 shows the change in the plasma Ca ′ level of the rat to which the compound K-222 of the present invention was administered.
- FIG. 54 shows the change in plasma Ca levels of rats receiving compound K-2 247 of the present invention:
- FIG. 55 shows the change in the plasma C a ⁇ ⁇ level of the rat to which the compound K-225 of the present invention was administered.
- FIG. 56 shows the change in plasma C a '-'- levels of rats receiving compound K-'2257 in the present invention:
- FIG. 57 shows the change in plasma Ca 2 — level of rats to which the compound K-222 of the present invention was administered.
- FIG. 60 shows the change in plasma Ca 2 — levels of rats receiving compound K-122 64 of the invention:
- rat plasma C a 2 of Bok compound K was administered one 2 2 6 5 of the present invention - showing the change in the level:
- FIG. 62 shows the change in the plasma Ca level of the rat to which the compound K-226 of the present invention was administered.
- FIG. 64 shows the change in plasma C a ⁇ level of lasosomal rats administered with the compound K-1 269 of the present invention.
- FIG. 65 shows the change in the plasma Ca 2 ′ level of the rat to which the compound K-1 270 of the present invention was administered.
- Fig. 67 shows the plasma Ca- 'level of rats to which the compound K-'227 of the present invention was administered. Indicates a change in
- FIG. 68 shows the change in plasma Ca ′ 2+ level of the rat to which the compound K-222 of the present invention was administered.
- FIG. 70 shows the change in the plasma Ca level of the rat to which the compound K-122 of the present invention was administered.
- FIG. 71 shows the change of the rat to which the compound K-122 of the present invention was administered. Shows changes in plasma C a 'levels:
- ⁇ 72 shows the change in plasma Ca 2- "level of the rats to which the compound K-12283 of the present invention was administered.
- FIG. 73 shows the change in the plasma Ca level of the rat to which the compound K-222 of the present invention was administered.
- FIG. 74 shows the change in the plasma Ca level of the rat to which the compound K-1 286 of the present invention was administered.
- FIG. 75 shows the change in plasma Ca levels of rats administered the compound K—2287 of the present invention:
- Compound K-2 plasma were rats Bok administered 2 8 9 C a 2 of the present invention - showing the change in the level
- FIG. 78 shows the change in the plasma Ca level of the rat to which the compound K-229 () of the present invention was administered.
- FIG. 79 shows the change in the plasma Ca ′ level of the rats to which the compound K-221 of the present invention was administered.
- FIG. 80 shows the change in plasma Ca 2 ′ level of rats to which the compound K-229 of the present invention was administered.
- Figure H1 shows the change in plasma Ca- 'levels of rats receiving compound K-229 of the present invention.
- Figure 82 shows the change in plasma Ca 'levels of rats receiving compound K-228 of the present invention:
- FIG. 83 shows the change in plasma Ca ′ level of rats to which the compound K-1 226 of the present invention was administered.
- FIG. 84 shows the change in the plasma Ca level of the rat to which the compound K-222 of the present invention was administered.
- FIG. 85 shows the change in plasma C a ⁇ level of rats treated with the compound K-122 988 of the present invention:
- FIG. 86 shows the change in plasma C a ' 2 — levels of rats receiving compound K-1229 of the present invention:
- FIG. 87 shows the change in plasma Ca levels of rats receiving compound K-230 of the present invention:
- FIG. 88 shows the change in plasma Ca levels of rats receiving compound K-1231 of the present invention:
- FIG. 89 shows the change in the plasma Ca 2 level of the rats to which the compound K—2302 of the present invention was administered——
- FIG. 90 shows the administration of the compound K—1233 of the present invention
- Rat plasma C a 2 — show changes in levels:
- Figure 91 shows the change in plasma Ca '"-level of rats receiving compound K-234 of the present invention:
- FIG. 93 shows the change in the plasma Ca level of the rat to which the compound K-2309 of the present invention was administered.
- FIG. 94 shows changes in plasma Ca- 'levels of rats to which the compound K-123I of the present invention was administered.
- FIG. 95 shows the change in the serum level of the rats to which the compound K-207, K-117 or K-225 of the present invention was administered.
- FIG. 96 shows that the compound of the present invention K-207, K-217 or K-225 Description of the preferred embodiment showing the change in the relative levels of the administered rats relative to the pre-dose levels of serum PTH
- the present invention describes an inorganic ion receptor modulator that mimics or blocks the effects of inorganic ions in an inorganic ion receptor.
- a preferred use of an inorganic ion receptor modulator is to treat a disease or disorder by modulating inorganic ion receptor activity.
- the molecule is an inorganic protein receptor modulator used to treat a disease or disorder characterized by abnormal protein homeostasis, more preferably abnormal calcium homeostasis.
- Applications eg, diagnostic applications, are described in Nemeth et al., I ⁇ CT / US93 /
- Calcium receptor pigs are cells of different types of tyres, such as parathyroid cells, osteoclasts, pararenal glomerular cells, proximal tubular cells, distal tubular cells, central nervous system cells, peripheral nervous system cells The cells of the thick ascending limb and the Z or collecting duct of Henle's lure, keratinocytes in the epidermis, parafollicular cells (c cells) in the thyroid, enterocytes, trophoblasts in the placenta, platelets, vascular smooth muscle cells, Present in atrial cells, gastrin-secreting cells, glucagon-secreting cells, renal glomerular stromal cells, mammary cells, hepatocytes, adipocytes, immune cells and gastrointestinal cells: Calcium receptors on these tyre
- calcium receptor pigs have a low affinity for extracellular Ca 2 — (apparent K d is generally higher than about 0.5 mM). Calcium receptors are free or bound. (Cooper, Bloom and Roth. "The Biochemical Basis oi ⁇ europharmacology", Ch. 4), which may be associated with intracellular calcium receptor (such as calmodulin and trophonin). Be separated:
- Calcium receptors respond to changes in extracellular calcium levels: the actual change depends on the particular receptor and the cell line containing the receptor—for example, on the calcium receptor in parathyroid cells In vitro effects of calcium include:
- Temporal addition may be due to activation of protein kinase C (KC), such as phorbol myristate acetate ( ⁇ ⁇ ⁇ ), mezerein 3 ⁇ 4 or (1) Blottin kinase (: total activator
- KC protein kinase C
- phorbol myristate acetate ⁇ ⁇ ⁇
- mezerein 3 ⁇ 4 mezerein 3 ⁇ 4
- Blottin kinase total activator
- Inorganic ion receptor modulators can elicit L or more inorganic ion receptor activities or block one or more inorganic ion receptor activities caused by extracellular inorganic ions: Calcium receptor modulators are calcium It also mimics the shadow of extracellular C a on the receptor.Also: block, preferred calcium receptor modulators are calcium mimetics and calcium antagonists.
- Inorganic ion receptor modulators can be identified by screening the designed molecule after it has been shown that the molecule has a specific activity (ie, a Lee molecule). Nemethetal., PC '!' / US 93/0 I 642 (International publication WO 94/1 8959) The preferred inorganic ion receptor modulators described according to the invention are very low
- EC 5 Is the concentration of the molecule that evokes half the maximum effect: : C 3 . Is the concentration of molecule that causes half the maximal blocking effect EC : also: tl C,. Can be determined by assessing the activity of one or more of the inorganic ions at the inorganic ion receptor.Preferably, such assays are specific for a particular calcium receptor. Preferred are assays that measure hormones whose production or secretion is regulated by specific inorganic ion receptors.
- Expressed cells such as parathyroid cells, osteoclasts, pararenal glomerular cells, proximal tubule cells, distal tubule cells, the thick ascending limb of the loop of Henle and cells of the Z or collecting ducts, in the epidermis Keratinocytes, parafollicular cells (C cells) in the thyroid, intestinal cells, central nervous system cells, peripheral nervous system cells, trophoblasts in the lunar base, platelets, vascular smooth muscle cells, atrial cells, gastrin secreting cells, Glucagon-secreting cells, renal glomerular interstitium Cells, mammary cells, beta cells, adipocytes, can be from immune cells and the gastrointestinal tract cells obtain poly (A) n RN A.
- the nucleic acid is obtained from parathyroid cells, C cells or osteoclasts.More preferably, the nucleic acid encodes a calcium receptor and is present on a brassamide or vector:
- the molecule is less 5 mu M in calcium receptacle ⁇ terpolymer, more favorable Mashiku is iota Myumyu less, 1 00 ⁇ , 1 0 ⁇ VI or 1 eta C 5 () or 1's I, '5.
- a calcium receptor modulator diminishes the secretion of parathyroid hormone from parathyroid cells at the mouth and reduces p ⁇ H secretion in vivo: calci from c cells in vitro Promotes tonin secretion and increases calcitonin levels in vivo: or blocks bone resorption by osteoclasts in vitro, inhibits bone resorption in vivo, whether it is a calcimimetic:
- the calcium receptor modulator is a calcium antagonist, which elicits secretion of parathyroid hormone from parathyroid cells at the mouth and increases the level of parathyroid hormone in vivo.
- the agent selectively targets an inorganic receptor activity, more preferably a calcium receptor activity, in a particular cell.
- “Selectively” means that two molecules are more or less defined. Means that for a given concentration of drug, it has a greater effect on inorganic ion receptor activity in one type of cell than in another type of cell: preferably, the difference in effect is 1 () times Or more.
- the concentration represents the plasma concentration and the effect measured is an extracellular messenger, such as plasma calcinin, parathyroid hormone or plasma calcium, etc.
- the drug is calcitonin secreting Selectively target ⁇ ⁇ ⁇ secretion as compared to:
- the molecule comprises parathyroid cells, osteoclasts, pararenal glomerular cells, proximal tubular cells, distal tubular cells, the thick ascending limb of Henle's Luer and Collecting duct cells, central nervous system cells, peripheral nervous system cells, keratinocytes in the epidermis :, parafollicular cells (C cells) in the thyroid gland, enterocytes, trophoblasts in the placenta, platelets, vascular smoothing One or more selected from the group consisting of muscle cells, atrial cells, gastrin-secreting cells, glucagon-secreting cells, renal glomerular stromal cells, glandular cells, beta cells, adipocytes, immune cells, and gastrointestinal cells , But not all cells have less than 1 ⁇ of RC (, or! C ; - strict)
- the inorganic ion receptor modulator is one that mimics or blocks all the effects of extracellular ions in cells that have inorganic ion receptor.
- a calcium receptor modulator is preferably a calcium receptor.
- calcimimetic agent need not have the biological activity of Te to base extracellular C a 2, at least mimic one such activity Similarly: Calcium antagonists need not reduce or prevent all activity caused by extracellular calcium. In addition, different calcimimetic agents and different calcium antagonists may not be able to show their effects. Calcium receptor: It is not necessary to bind to the same site as extracellular Ca2 on the receptor- II .
- a calcimimetic umbi
- the temporary increase in [C a ']; caused by the molecule is due to the activator of arotinkinase-zetase C (P KC), such as phorbol myristate (1) mezerein or (1) indolactam V Decreased by pretreatment with e.g.-the overall effect of the kinase 'activator of kinase C !, by shifting the concentration-response curve of the molecule to the right without affecting the maximum response.
- P KC arotinkinase-zetase C
- Molecule is dohamin-one or isobroterenol-stimulated cyclic AM
- Molecules induce an increase in C1 currents in Xenopus oocytes injected with poly (A) 'aura mRNA from human or parathyroid cells, but not in water or rat. It does not affect A. frog oocytes injected with brain or liver mRNII:
- the molecule when using a cloned calcium receptor from parathyroid cells, the molecule would be an African oocyte injected with a specific cDNA or mRNA molecule that binds to the receptor. Will trigger a cellular response:
- Nemethet al. PCT / US93 / 01642 (International Publication WO94 / 189559): other A similar definition of a molecule that mimics Ca 2 — activity in calcium responsive cells, preferably in the calcium receptor, is found herein and in Nemeth et al., PCT / US 93/0 16 4 2 ( It is evident from the examples provided in International Publication WO94 / '189559)
- the drug is obtained from a bi-yearly atsushi described herein or in Nemeth et al., PCT / US93 / 01642 (WO 94/189595). Measured to have one or more, and more preferably all, of the following activities: evokes a transient increase in intracellular calcium (preferably by translocating intracellular calcium) for less than 3 () seconds With a lag time: evokes a rapid (causing within 30 seconds) increase in [C a-] i: evokes a continuous increase (greater than 30 seconds) in [C a ⁇ :, (preferably cells) By causing the influx of extracalcium): Inositol-I, 4, ⁇ ) —Triphosphate or diacylglycerol
- V2 Evokes an increase in the level of the drug (preferably for less than 60 seconds): and inhibits dohamin- or isobroterenol-stimulated cyclic AMP formation
- Temporary increases in [Ca-] preferably, the force or transient increase prevented by pretreating the cells with 10 mM sodium fluoride for 10 min.
- a molecule to block the activity of extracellular calcium can be determined using standard methods.
- Emeth et al., PC TZ J S93 / 01642 International Publication W 094/18959 :
- molecules that block the effects of extracellular calcium when used on epidermal cells, have one or more, and preferably all, of the following activities when tested on parathyroid cells in vitro: the held: 1. molecules, partially or completely, blocks the following capability of extracellular C a 2 'concentrations ⁇ :
- Molecules are induced by extracellular Ca 2 — or calcimimetic CI-currents in African oocytes injected with Hori (A) ”mRNA from red or human parathyroid cells But not in water or liver mRNA-infused A. frog oocytes:
- the molecule encodes a calcium receptor specific c 1] ⁇ 8, ⁇ ⁇ ⁇ ⁇ , or c [ Extracellular C a-'or Cal of Xenopus oocytes injected with ⁇ Prevent responses elicited by shimimetic compounds
- a preferred use of the compounds described by the present invention is to treat or prevent different diseases or disorders by modulating inorganic ion receptor activity:
- the inorganic ion receptor modulators of the present invention affect inorganic ion receptors, It causes one or more cellular effects and ultimately produces a therapeutic effect: By targeting cells with inorganic ion receptors, such as calcium receptors, different diseases and diseases according to the present invention.
- HPT primary hyperparathyroidism
- PTH circulating protein
- C a extracellular C a 2 shifts to "set point" is right against one, therefore outside higher than normal cells to suppress PTH secretion C a ⁇
- primary HPT often only partially inhibits PT! I secretion, even at high extracellular C a concentrations: in secondary (uremic) HPT, C a : — inhibits It is observed that the set point for extracellular C a is also increased, even if the degree of PTH secretion is normal.
- Molecules that mimic the action of extracellular Ca are useful in long-term management of both primary and secondary ⁇ PT: Beneficial molecules such as T11 cannot be achieved by hypercalcemic conditions alone. Provides extracellular stimuli necessary for secretion suppression, thereby helping to reduce hypercalcidic states Extracellular 'a-up molecule with high potency may be particularly troublesome in adenomatous tissue Can conquer the obvious non-suppressible factors of In addition or additionally, such molecules may have been shown to have been shown to suppress the levels of prepro PTH mR ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ in thymic and human adenomatous parathyroid tissues, Synthesis of ⁇ ⁇ ⁇ can be suppressed. Long-term hypercalcemia also inhibits the proliferation of parathyroid cells in vitro, and therefore, calcium mimetics are also effective at limiting the parathyroid cell hyperplasia characteristic of secondary ⁇ . Yes')
- Cells other than parathyroid may direct response to physical changes in the extracellular C a 2 concentrations.
- calcitonin secretion from parafollicular cells (C cells) in the thyroid is regulated by changes in the concentration of extracellular Ca.
- Isolated osteoclasts respond to increases in the concentration of extracellular C a 2 over which the pair JT, to, in part resulting from the movement of intracellular C a [C a 2 i is ⁇ in osteoclasts Okero: increase in C a 2 i, the release of Al force Rihosufata Ichize from osteogenic osteoclasts with inhibition of bone resorption is directly stimulated by calcium c
- Intracellular C a 2 causes: Other renal cells that respond to calcium are: elevated C a 2 inhibits the formation of 125 (OH) 2 —vitamin D by proximal tubule cells and distal urine stimulates the production of calcium-binding proteins in tubule cells, and inhibits the action of vasopressin on the medullary thick top limb of C a 2 and VI g 2 of tubular reabsorption and Henle Le part (VI TAL), the cortical collecting duct Decreases the effect of vasopressin on cells and affects vascular smooth muscle cells in renal glomerular blood vessels: Calcium also promotes differentiation of intestinal gubrel cells, thyroid cells and skin cells, and atrial from atria Naturimu diuretic petit Inhibits the secretion of
- the C a 2 is in addition to the important role as its intracellular signaling, there is sufficient indication to suggest that also controls the response of specific cells are to function as fine extracellular signal
- the molecule of the invention is a novel
- Certain diseases and disorders that can be treated or prevented based on the cells affected include stroke, stroke, head trauma, spinal cord injury, hypoxia-induced neuronal damage (eg, cardiac arrest or neonatal distress).
- Epilepsy neurodegenerative diseases (for example, Alzheimer's disease, Huntington's disease and Parkinson's disease), dementia, muscle tone, depression, anxiety, depression, obsessive-compulsive disorder, post-traumatic stress Diseases and disorders of the central nervous system, such as respiratory illness, schizophrenia, malignant neuroleptic syndromes, and Tourette's syndrome: inadequate AD H secretion (SI AH) syndrome, liver cirrhosis, heart failure and nephrosis, etc.
- SI AH inadequate AD H secretion
- the inorganic ion receptor modulators of the present invention are typically used for the treatment of patients in baboons, and they can be used to treat other warm-blooded animal species, for example, other primates, and livestock such as pigs, cattle, poultry, and the like. Can be used to treat similar or identical diseases or disorders in competing animals and heads such as horses, dogs and cats
- the compound of the present invention may be administered as such or in a pharmaceutical composition prepared by mixing it with a suitable carrier or excipient.
- a suitable carrier or excipient can be administered to patients, techniques for drug prescribing and administration ⁇ ; Remingtons Pharmaceutical Sciences, ackublishing Co., F. ast. On, PA ⁇ 7)
- the administration of ion mimetics and anti-tin antagonists is discussed in emeth, eLaI., CT / US 9/01642 (WO 4 ⁇ 18959).
- a “pharmaceutical composition” is one or more of the compounds disclosed herein, or a pharmaceutically acceptable salt, hydrate or lip of the present invention;
- the purpose of a pharmaceutical composition is to facilitate administration of the compound to an organism.
- “Prodrug” refers to a drug that is converted to the parent drug in vivo. Brodrug is often useful because it is sometimes easier to administer than the parent drug, for example, Bioavailability upon administration, but not the parent drug Also, the drug may have improved solubility in pharmaceutical compositions relative to the parent drug.
- Examples of drug drugs Is administered as an ester ("prodrug") to facilitate transport across cell membranes (where water solubility is not an advantage), but then into the cell (where water solubility is an advantage).
- Compounds of the present invention that, once entered, are metabolically hydrolyzed to carboxylic acids, but are not limited to:
- esters refers to a carboxyl group as defined herein, wherein R ′′ is any group other than hydrogen among the groups described.
- physiologically acceptable carrier n representing not cause no significant irritation to an organism, a carrier or diluent that does not abrogate the biological activity and properties of the administered compound
- Excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound.
- excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, Include, but are not limited to, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycol.
- Suitable forms are dependent, in part, on the use and the route of injection (eg, oral, transdermal or injection): such forms may be present in culture even when the target cells are present in a multicellular host. Even if present, it must allow the drug to reach the target cells.
- a pharmaceutical formulation or composition that is infused into the bloodstream must be soluble at the concentrations used. Factors are known in the art, including, for example, considering toxicity and forms that prevent the drug or composition from exerting its effect.
- the drug may also be formulated as pharmaceutically acceptable salts (eg, acid addition salts) and complexes thereof.
- pharmaceutically acceptable salts eg, acid addition salts
- the preparation of such salts may interfere with imparting the physiological effect of the drug.
- Pharmacologic use is possible by altering the physical properties of the drug without the need for transmucosal administration by lowering the melting point. Includes ease of use and increased solubility to allow for higher drug concentration
- the molecules of the invention are preferably in liquid solution, preferably.
- the molecule can be formulated in a physiologically compatible buffer such as Hank's solution or Ringer's solution.
- the molecule can be formulated as a solid and redissolved or suspended immediately before use. It can also be manufactured: can be administered systemically by a transmucosal or transdermal method, or the molecule can be administered orally: for transmucosal or transdermal administration, it can be applied to the septum to be permeated.
- penetrants are generally known in the art, and include, for example, bile salts and fusidic acid derivatives for transmucosal administration.
- Surfactants can also be used to facilitate penetration: Transmucosal administration can be through, for example, fecal arrays, or using suppositories.
- the molecule can be converted into carcels, tablets, and tonics. Prescribed in conventional oral dosage forms of
- the molecules of the invention are formulated into ointments, salves, gels, or creams as generally known in the art.
- a therapeutically effective amount is the EC5. Or ⁇ C 5.
- the molecule is about ln! 33 ⁇ , preferably () .1 ⁇ -1 ⁇ : Generally, about 0.1-50 mg, preferably (0.1) -20 mg / kg of animal to be treated.
- Examples 1-2 Here, the compounds shown in FIG. 1 were synthesized; the compounds of the present invention wherein X is O in formula (1) were used as starting materials for 2—, 3— or 4 with phenol was synthesized according to the scheme of Figure 2, X in the formula (1) is: a would present invention (Ri compound 2 as output 3 ⁇ 4 raw material - was with dimensions 4 one Kurorochiofuyu Nord, Figure: Synthesized according to scheme 5
- Examples 24 to 36 the compounds of the present invention were synthesized according to the schemes shown in FIGS. 5 to 7.
- the target compound 18 was obtained by the same two steps using 1,6-dibumohexane instead of 4-dibromobutane.
- the target compound 24 was obtained by the same two steps using 5-dibromohentane instead of 1,3-dibromobrohan.
- the reaction was carried out at 45 C for 3 hours under ripening reflux. After the reaction was completed, the methylene chloride was once removed under reduced pressure. 500 mg (3.62 mmo 1) was added, and then (R) — 3 — methoxy — ⁇ -methylbenzylamine: 350 mg (2.31 mmo 1) was added dropwise. The mixture was stirred under heating and reflux at 90 : C for 12 hours. After completion of the reaction, the mixture was allowed to cool at room temperature, and water was poured []: Then, ethyl acetate and saturated saline were used, respectively. Separation extraction and washing were performed, and the obtained organic layer was dried over sodium sulfate.
- the target compound 34 was obtained in the same two steps by using 6-jib mouth molexane instead of the 1,3-jib mouth moalohan.
- the target compound 40 was obtained in the same two steps using 1,6-dibumohexane instead of 1,5-dibromohentane.
- the target compound 44 was obtained by the same two steps.
- 1,4-Dibromobutane was replaced by 1,6-dibumohexane to give the desired compound 46 in two identical steps ;
- a c OE t layer are water and saturated N a C 1 aq. and washed with., dried over Na 2 S0 4, the solvent was evaporated under reduced pressure The resulting residue was purified by column chromatography [silica gel, AcOEt-n-hexane] to give a colorless oil 73 (551.8 mg, 100%):
- CH 2 C 1 is c CH 2 C 1 2-layer extracted with 2 5% HC 1 aq., Washed with water and then a saturated N a C 1 aq., Dried over N a 2 S 0 4, The solvent was distilled off, and the obtained crystals were purified by column chromatography [silica gel, n-hexane-AcOEt], and then colorless prism crystals 85 (790.0 mg, 98.4%) ).
- reaction solution was poured into water, extracted with ethyl acetate, and the ethyl acetate layer was washed with water and saturated saline: dried over sodium sulfate, and the solvent was distilled off under reduced pressure.
- the resulting residue was purified by column chromatography [silica gel, ethyl acetate-n-hexane] to obtain compounds 102, 361.8 mg (80.0%) as colorless prism crystals.
- reaction solution was poured into water.
- the mixture was extracted with ethyl acetate.
- the ethyl acetate layer was dried over sodium sulfate washed with water and saturated saline, and the solvent was distilled off under reduced pressure.
- the resulting residue was purified by column chromatography [silica gel, ⁇ -ethyl-n-hexane] to give 103, 67.1 mg (89.5%) of compound as a colorless oil.
- reaction solution was poured into water.
- the mixture was extracted with ethyl acetate.
- the ethyl acetate layer was washed with water and saturated saline. After drying over sodium sulfate, the solvent was distilled off under reduced pressure. I left.
- the resulting residue was purified by column chromatography [silica gel, ethyl acetate-n-hexane] to obtain compound 111,586 (61.4%) as a colorless oil. .
- reaction solution was poured into water, extracted with ethyl acetate, the ethyl acetate layer was washed with water and saturated saline, dried over sodium sulfate, and the solvent was distilled off under reduced pressure.
- the resulting residue was purified by column chromatography [silica gel, ethyl acetate-n-hexane] to give compound 112, 36.5 mg (62.0%) as a colorless oil,
- reaction solution was poured into water: Dicuco extract extracted with dichloromethane The methane layer was washed with 5% aqueous hydrochloric acid, water, and then with saturated saline, dried over sodium sulfate, and the solvent was distilled off. The resulting crystals were purified by column chromatography: silica gel, ethyl acetate-n-hexane], and compound 114 (66.29 mg, 66.5%) was converted into colorless prisms. Obtained
- reaction solution was concentrated, acidified with a 5% aqueous hydrochloric acid solution, and the reaction solution was extracted with ethyl acetate added to water.
- the ethyl acetate layer was extracted with a 5% aqueous hydrochloric acid solution, water, and then.
- After washing with a saturated saline solution the mixture was dried over sodium sulfate, and the solvent was distilled off.
- Compound 1 2 3 Compound 1 2 2 (150 mg, 0.51 mmo 1) and (R)-(+) — 1— (1-naphthyl) ethylamine (104.5 mg, 0.61 mmo) 1, 1.2 mo 1 eq.) Were dissolved in chloroform-methanol (3 mi) and left at room temperature for 1 week.
- reaction solution was allowed to cool at room temperature, water was added, liquid separation and extraction were performed with a black hole form, and the extract was washed with saturated brine.
- the obtained organic layer was dried using anhydrous sodium sulfate and concentrated under reduced pressure.
- reaction solution was allowed to cool at room temperature, water was added, liquid separation and extraction were performed with a black hole form, and the extract was washed with saturated brine.
- reaction solution was left to cool at room temperature, water was added, liquid separation and extraction were performed with a black hole form, and the mixture was washed with saturated brine.
- reaction solution was allowed to cool at room temperature, water was added, liquid separation and extraction were performed with a black hole form, and the extract was washed with saturated brine.
- reaction solution was allowed to cool at room temperature, water was added, liquid separation and extraction were performed with a black hole form, and the mixture was washed with a saturated saline solution.
- 3_Bromobenzenethiol 6 10 mg (3.22 mm oi) was dissolved in 10.0 m 1 of acetonitrile, and potassium carbonate 49 O mg (3.55 mm o 1) at room temperature. 1,8-Dibromooctane () .59 ml (3.20 mm o 1) was added sequentially, and the mixture was stirred at the same temperature for 1 hour. After confirming the completion of the reaction by TLC, the mixture was stirred at room temperature.
- 3,4-Dichlorobenzenethiol (556 mg, 3. ll mmol) was dissolved in acetate nitrile (12.Om1), and potassium carbonate (41,2 mg, 2.99 mmo1) was added at room temperature. ), 1,4-Dibromobutane 0.37 ml (3.10 mm o 1) was added in 1 (1 page next) and stirred for 1 hour at the same temperature. After confirming the completion of the reaction by TLC, At room temperature, potassium carbonate 2 242 mg (1.75 mm o 1), (R) mono (+) — 3-methyl ⁇ -methylbenzylamine 28 O mg (1.85 mm o) 1) was added to the reaction system, and the mixture was further stirred at 100 for 24 hours.
- reaction solution was allowed to cool at room temperature, water was added, liquid separation and extraction were performed with a black hole form, and the mixture was washed with a saturated saline solution.
- 3,4-Dichlorobenzenethiol 5 15 mg (2.88 mmol) was dissolved in 11.0 ml of acetate nitrile and, at room temperature, potassium carbonate 41 Omg (2.97 mmo 1), 0.39 ml (2.86 mmol) of 1,5-dibromopentane was sequentially added, and the mixture was stirred at the same temperature for 1 hour. After confirming the completion of the reaction by TLC, the mixture was stirred at room temperature for lithium carbonate. 2 30 mg (1.66 mmo 1), (R) 1 () 13-Methoxy-1- ⁇ -methylbenzylamine 26 Omg (1.72 mmo 1) was added to the reaction system, and 1 00 : The mixture was stirred at C for 24 hours.
- 2,4-Dichloromouth benzenethiol 540 mg (3.02 mmol) was dissolved in 11.0 ml of acetonitrile, and potassium carbonate 42O mg (3.04 mm o 1), 0.31 ml (3.05 mmol) of 1,3-dibromobroban were sequentially added, and the mixture was stirred at the same temperature for 1 hour. After confirming the completion of the reaction by TLC, the mixture was cooled to room temperature. 234 mg (1.69 mm o 1), (R)-(+) — 3-Methoxy ⁇ -methylbenzylamine at 230 mg (1.52 mm o) I) was added to the reaction system, and the mixture was further stirred at 100 C for 24 hours.
- reaction solution was poured into water and extracted with chloroform.
- foam layer was washed with water and saturated saline: dried over sodium sulfate and lithium, and then dried.
- the crystals obtained were purified by column chromatography (silica gel, chloroformumethanol) to give colorless arrhythmic crystals (1.085 g, 85.0%).
- Conjugated ketone body 208 (10 Om g, 0.3 1 mm o 1) and (R) — (+) — 1-(1 naphthyl) ethylamine (6 4.2 mg, 0.38 mm o 1 , 1.2 m ⁇ 1 eq.) was dissolved in chloroform-methanol (4: 1) and allowed to stand at room temperature for 1 week. After the reaction was completed, the solvent was distilled off under reduced pressure. Colorless oil after purification by column chromatography [silica gel, silica gel form] K 2 250
- Benzaldehyde 50 () mg, 4.71 mm ⁇ 1) and 3-clozen benzylamine (666.2 mg, 4.71 mm o 1, 1.0 mo 1 eq.); After adding tritium broxide (1.67 ml, 5.6.5 mmol, 1.2 moleq.), The mixture was stirred at room temperature for 4 hours. After the reaction was completed, the reaction mixture was dissolved in ethanol. , Sodium borohydride (712.7 mg, 18.84 mmo 1, 4.Omo 1 eq.) Were added, and the mixture was stirred at room temperature for 12 hours. After the reaction was completed, the pressure of the solvent was reduced.
- Conjugated ketone body 2 18 (800 mg, I. 63 mmo 1) and (R) — (+) — 1-(1 naphthyl) ethylamine (33.4.7 mg, 1.95 mm o, 1.2 mo I eq.) was dissolved in chloroform-methanol (4: 1) and left at room temperature for 1 week. After the reaction was completed, the solvent was distilled off under reduced pressure and the obtained oil was subjected to column chromatography. Colorless oil K- '2 25 after purification with silica gel, silica gel
- Dibenzylamine 2 25 (315 mg, 0.94 mm o 1) and triethynoleamine (0.16 ml, 1.1 3 mm o 1.1.2 mo 1 eq.) was dissolved in ice-cold form, and acryloyl chloride mouth liquid (94 mg, 1.04 mmo 1, 1.1 mo I eq.) Dissolved in black-mouthed form was added thereto, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was poured into water and extracted with chloroform. The chloroform layer was washed with water and saturated saline, dried over sodium sulfate, and the solvent was distilled off under reduced pressure.
- the obtained oil was purified by column chromatography [silica gel, black-mouthed form] to obtain a colorless oil 2 26 (347.1 mg, 94.9%)-VIS / z 38 9, 'H-NR ⁇ : 4.47 (2 ⁇ , s, C ⁇ ), 4.
- Dibenzylamine 2229 (800 mg, 2.66 mm o 1) and triethylamine (0.45 m to 3.19 mm o 1, 1.2 m ⁇ 1 eq.) Under ice-cooling, add acryloyl-clad mouth (265 mg, 2.93 mmo1, 1.1 mo 1 eq.) Dissolved in black-mouthed form under ice cooling, and add 30 ml at room temperature. After the completion of the reaction, the reaction solution was poured into water, and the mixture was extracted with chloroform. The foam layer was washed with water and saturated saline, dried over sodium sulfate, and the solvent was removed. The oil obtained was purified by column chromatography [silica gel, silica gel form] to give a colorless oil 2:30 (76.8.9 mg, 81.4%).
- Dibenzylamine 23 (50 O mg, 1.43 mm o 1) and triethylamine (0.238 ml. 1.7 1 mm o 1.1.2 mo 1 eq.) Under ice-cooling, and add Acryloyluk mouth-ride (142 mg, 1.7 mmo1, 1.1 mo1 eq.) Dissolved in black-mouthed form under ice-cooling, and allow to stand at room temperature for 30 minutes. After completion of the reaction, the reaction solution was poured into water and extracted with chloroform. The foam layer was washed with water and saturated saline, dried over sodium sulfate, and then the solvent was decompressed. The oil obtained by distillation was purified by column chromatography [silica gel, chloroform] to give a colorless oil 234 (454.6 mg, 78.7%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69740158T DE69740158D1 (de) | 1996-07-08 | 1997-07-08 | Verbindungen die die aktivität von calcium-rezeptoren beeinflussen |
AU33597/97A AU734710B2 (en) | 1996-07-08 | 1997-07-08 | Calcium receptor active compounds |
AT97929555T ATE503739T1 (de) | 1996-07-08 | 1997-07-08 | Verbindungen die die aktivität von calcium- rezeptoren beeinflussen |
JP50505898A JP4331264B2 (ja) | 1996-07-08 | 1997-07-08 | カルシウムレセプター活性化合物 |
EP97929555A EP0933354B1 (en) | 1996-07-08 | 1997-07-08 | Calcium receptor-active compounds |
US09/214,552 US6362231B1 (en) | 1996-07-08 | 1997-07-08 | Calcium receptor active compounds |
CA002259922A CA2259922C (en) | 1996-07-08 | 1997-07-08 | Calcium receptor active compounds |
HK00100020A HK1020942A1 (en) | 1996-07-08 | 2000-01-03 | Calcium receptor-active compounds |
US10/326,713 US6939895B2 (en) | 1996-07-08 | 2002-12-19 | Calcium receptor-active compounds |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8/178315 | 1996-07-08 | ||
JP17831596 | 1996-07-08 | ||
JP8/350393 | 1996-12-27 | ||
JP35039396 | 1996-12-27 | ||
JP10777897 | 1997-04-24 | ||
JP9/107778 | 1997-04-24 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/214,552 A-371-Of-International US6362231B1 (en) | 1996-07-08 | 1997-07-08 | Calcium receptor active compounds |
US09214552 A-371-Of-International | 1997-07-08 | ||
US10/053,133 Continuation US6750255B2 (en) | 1996-07-08 | 2002-01-17 | Calcium receptor-active compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998001417A1 true WO1998001417A1 (fr) | 1998-01-15 |
Family
ID=27311070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/002358 WO1998001417A1 (fr) | 1996-07-08 | 1997-07-08 | Composes actifs comme recepteurs du calcium |
Country Status (13)
Country | Link |
---|---|
US (5) | US6362231B1 (ja) |
EP (1) | EP0933354B1 (ja) |
JP (2) | JP4331264B2 (ja) |
KR (2) | KR100860655B1 (ja) |
CN (1) | CN1131202C (ja) |
AT (1) | ATE503739T1 (ja) |
AU (1) | AU734710B2 (ja) |
CA (1) | CA2259922C (ja) |
DE (1) | DE69740158D1 (ja) |
ES (1) | ES2364179T3 (ja) |
HK (1) | HK1020942A1 (ja) |
TW (1) | TW510896B (ja) |
WO (1) | WO1998001417A1 (ja) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713473B1 (en) | 1999-04-20 | 2004-03-30 | Meiji Seika Kaisha, Ltd. | Tricyclic compounds |
US6908935B2 (en) | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
US6967216B2 (en) | 2000-05-05 | 2005-11-22 | Astrazeneca Ab | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor |
US7176322B2 (en) | 2002-05-23 | 2007-02-13 | Amgen Inc. | Calcium receptor modulating agents |
US7361789B1 (en) | 2004-07-28 | 2008-04-22 | Amgen Inc. | Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis |
US7408064B2 (en) | 2001-09-11 | 2008-08-05 | Astrazeneca Ab | Carbazole derivatives and their use as NPY5 receptor antagonists |
JP2009507017A (ja) * | 2005-09-02 | 2009-02-19 | アムジエン・インコーポレーテツド | 腸液バランスを調節する方法 |
EP2127654A1 (en) * | 2004-03-25 | 2009-12-02 | The Trustees of Columbia University in the City of New York | Benzothiazepine derivatives as ryanodine receptor (RYR2) inhibitors and their use in the treatment of cardiac diseases |
WO2010136035A2 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
WO2010136037A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
WO2010150837A1 (ja) * | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
WO2012000498A1 (en) | 2010-06-30 | 2012-01-05 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
WO2012000499A1 (en) | 2010-06-30 | 2012-01-05 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
WO2012069419A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
WO2012069402A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Substituted cyclopentyl - azines as casr- active compounds |
WO2012069420A2 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
WO2012069421A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
US8362274B2 (en) | 2004-05-28 | 2013-01-29 | Mitsubishi Tanabe Pharma Corporation | Arylalkylamine compound and process for preparing the same |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE503739T1 (de) * | 1996-07-08 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Verbindungen die die aktivität von calcium- rezeptoren beeinflussen |
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7393652B2 (en) | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
JP2007525165A (ja) | 2003-03-07 | 2007-09-06 | トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | タイプ1ライアノジン受容体に基づく方法 |
US7288253B2 (en) | 2003-08-08 | 2007-10-30 | Amgen Fremont, Inc. | Antibodies directed to parathyroid hormone (PTH) and uses thereof |
US7318925B2 (en) * | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
PT2821067T (pt) | 2003-09-12 | 2017-12-01 | Amgen Inc | Formulação de cinacalcet de dissolução rápida |
WO2005065050A2 (ja) | 2003-12-25 | 2005-07-21 | Asahi Kasei Pharma Corporation | 2環化合物 |
DE102004010830A1 (de) * | 2004-02-27 | 2005-09-15 | Bioagency Ag | Neue 1,4-Benzooxazepane oder 1,4-Benzothiazepane und Derivate |
US7531518B2 (en) * | 2004-05-14 | 2009-05-12 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
US7648965B2 (en) * | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
WO2006015279A1 (en) * | 2004-07-28 | 2006-02-09 | Neurogen Corporation | Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders |
KR20070116817A (ko) * | 2005-03-17 | 2007-12-11 | 암젠 인코포레이티드 | 석회화를 감소시키는 방법 |
US20060293667A1 (en) * | 2005-05-19 | 2006-12-28 | Agnes Vignery | Bone implant device and methods of using same |
US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
EP2573833B1 (en) | 2005-12-12 | 2014-04-02 | Basf Se | Organic semiconductors, their manufacture and semiconductor devices comprising them |
JP5309014B2 (ja) | 2006-03-23 | 2013-10-09 | アムジエン・インコーポレーテツド | シナカルセットの多形体の製造および使用のための方法および組成物 |
KR20080110681A (ko) * | 2006-04-20 | 2008-12-18 | 암겐 인코포레이티드 | 안정적 에멀젼 조제물 |
EP2139462B1 (en) | 2007-03-30 | 2014-01-22 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
CN117430522A (zh) * | 2022-07-14 | 2024-01-23 | 浙江友宁生物医药科技有限公司 | 一种gpr139受体激动剂及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2767168A (en) * | 1953-02-20 | 1956-10-16 | Bristol Lab Inc | Purification of streptomycin |
US2770653A (en) * | 1955-03-09 | 1956-11-13 | American Home Prod | Diaralkylalkylenediamine preparation |
US2868833A (en) * | 1952-08-26 | 1959-01-13 | American Home Prod | Aliphatic diamines and salts thereof |
US2876236A (en) * | 1952-08-26 | 1959-03-03 | American Home Prod | Heterocyclic diamines and salts thereof |
GB982572A (en) * | 1960-06-10 | 1965-02-10 | Wellcome Found | Improvements in and relating to quaternary ammonium compounds and the preparation thereof |
WO1993004373A1 (en) | 1991-08-23 | 1993-03-04 | Nps Pharmaceuticals, Inc. | Calcium receptor active molecules |
WO1994018959A1 (en) | 1993-02-23 | 1994-09-01 | Brigham And Women's Hospital, Inc. | Calcium receptor-active molecules |
WO1995011221A1 (en) | 1991-08-23 | 1995-04-27 | Nps Pharmaceuticals, Inc. | Calcium receptor-active arylalkyl amines |
WO1996012697A2 (en) | 1994-10-21 | 1996-05-02 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH480307A (de) * | 1966-06-03 | 1969-10-31 | Ciba Geigy | Verfahren zur Herstellung von schwefelhaltigen Aminen |
DK368687A (da) * | 1986-11-21 | 1988-05-22 | Cheminova As | Aminoalkylerede hydroxyforbindelser og deres anvendelse som fungicider |
FR2646847B1 (fr) * | 1989-05-12 | 1991-07-12 | Rhone Poulenc Sante | N-phenyl amides, leurs procedes de preparation et les medicaments les contenant |
EP0734370B1 (fr) | 1994-10-19 | 1999-10-20 | Firmenich Sa | Procede pour la preparation d'alcools |
JP4117506B2 (ja) * | 1996-05-01 | 2008-07-16 | エヌピーエス ファーマシューティカルズ インコーポレイテッド | 無機イオン活性化合物 |
ATE503739T1 (de) * | 1996-07-08 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Verbindungen die die aktivität von calcium- rezeptoren beeinflussen |
-
1997
- 1997-07-08 AT AT97929555T patent/ATE503739T1/de not_active IP Right Cessation
- 1997-07-08 US US09/214,552 patent/US6362231B1/en not_active Expired - Fee Related
- 1997-07-08 ES ES97929555T patent/ES2364179T3/es not_active Expired - Lifetime
- 1997-07-08 KR KR1019997000098A patent/KR100860655B1/ko not_active Expired - Fee Related
- 1997-07-08 TW TW086109630A patent/TW510896B/zh not_active IP Right Cessation
- 1997-07-08 WO PCT/JP1997/002358 patent/WO1998001417A1/ja active Application Filing
- 1997-07-08 KR KR1020067026010A patent/KR100771092B1/ko not_active Expired - Fee Related
- 1997-07-08 AU AU33597/97A patent/AU734710B2/en not_active Ceased
- 1997-07-08 CN CN97196285A patent/CN1131202C/zh not_active Expired - Fee Related
- 1997-07-08 DE DE69740158T patent/DE69740158D1/de not_active Expired - Lifetime
- 1997-07-08 CA CA002259922A patent/CA2259922C/en not_active Expired - Fee Related
- 1997-07-08 JP JP50505898A patent/JP4331264B2/ja not_active Expired - Fee Related
- 1997-07-08 EP EP97929555A patent/EP0933354B1/en not_active Expired - Lifetime
-
2000
- 2000-01-03 HK HK00100020A patent/HK1020942A1/xx not_active IP Right Cessation
-
2002
- 2002-01-17 US US10/053,133 patent/US6750255B2/en not_active Expired - Fee Related
- 2002-11-21 US US10/243,322 patent/US20030176485A1/en not_active Abandoned
- 2002-12-19 US US10/326,713 patent/US6939895B2/en not_active Expired - Fee Related
-
2003
- 2003-03-13 US US10/389,093 patent/US7816408B2/en not_active Expired - Fee Related
-
2007
- 2007-01-11 JP JP2007003556A patent/JP4140859B2/ja not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2868833A (en) * | 1952-08-26 | 1959-01-13 | American Home Prod | Aliphatic diamines and salts thereof |
US2876236A (en) * | 1952-08-26 | 1959-03-03 | American Home Prod | Heterocyclic diamines and salts thereof |
US2767168A (en) * | 1953-02-20 | 1956-10-16 | Bristol Lab Inc | Purification of streptomycin |
US2770653A (en) * | 1955-03-09 | 1956-11-13 | American Home Prod | Diaralkylalkylenediamine preparation |
GB982572A (en) * | 1960-06-10 | 1965-02-10 | Wellcome Found | Improvements in and relating to quaternary ammonium compounds and the preparation thereof |
WO1993004373A1 (en) | 1991-08-23 | 1993-03-04 | Nps Pharmaceuticals, Inc. | Calcium receptor active molecules |
JPH06510531A (ja) * | 1991-08-23 | 1994-11-24 | エヌピーエス・ファーマシウティカルズ・インコーポレイテッド | カルシウム受容体活性化分子 |
WO1995011221A1 (en) | 1991-08-23 | 1995-04-27 | Nps Pharmaceuticals, Inc. | Calcium receptor-active arylalkyl amines |
WO1994018959A1 (en) | 1993-02-23 | 1994-09-01 | Brigham And Women's Hospital, Inc. | Calcium receptor-active molecules |
WO1996012697A2 (en) | 1994-10-21 | 1996-05-02 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
Non-Patent Citations (15)
Title |
---|
"Calcium-Binding Proteins in Health and Disease", 1987, ACADEMIC PRESS, INC., pages: 33 - 35 |
BIOSCIENCE REPORTS, vol. 10, 1990, pages 493 |
BROWN ET AL., ENDOCRINOLOGY, vol. 128, 1991, pages 3047 |
CHEMICAL ABSTRACTS, Vol. 51, (1957), (Columbus, Ohio, USA), Abstract No. 7428i, LEE C. CHENEY, "Purification of Streptomycin"; & US,A,2 767 168. * |
CHEMICAL ABSTRACTS, Vol. 53, (1959), (Columbus, Ohio, USA), Abstract No. 12303e, JOSEPH L. SZABO et al., "Heterocyclic Diamines and Salts"; & US,A,2 876 236. * |
CHEMICAL ABSTRACTS, Vol. 53, (1959), (Columbus, Ohio, USA), Abstract No. 8788d, ROY S. HAUSLICK et al., "Diaralkylenediamine"; & US,A,2 770 653. * |
CHEMICAL ABSTRACTS, Vol. 53, (1959), (Columbus, Ohio, USA), Abstract No. 9251b, JOSEPH L. SZABO et al., "Aliphatic Diamines and Their Salts"; & US,A,2 868 833. * |
CHEMICAL ABSTRACTS, Vol. 60, (1964), (Columbus, Ohio, USA), Abstract No. 11246g, ROBERT P. HALLIDAY et al., "Evaluation of Certain Hypotensive Agents. V. Substituted Polymethylene Diamines"; & J. PHARM. SCI., 53(1), (1964), p. 19-23. * |
CHEMICAL ABSTRACTS, Vol. 60, (1964), (Columbus, Ohio, USA), Abstract No. 1692c, JERRY E. ROBERTSON et al., "Hypotensives. VI. Disubstituted Alkylenediamines and Related Compounds"; & J. MED. CHEM., 6(6), 1963, p. 805-807. * |
CHEMICAL ABSTRACTS, Vol. 60, (1964), (Columbus, Ohio, USA), Abstract No. 4920f, L. SCHUSTERITZ et al., "Structure and Action of Piperazine and Ethylenediamine Derivatives"; & ARZNEIMITTEL-FORSCH., 9, (1959), p. 628-633. * |
CHEMICAL ABSTRACTS, Vol. 63, (1965), (Columbus, Ohio, USA), Abstract No. 2928b, WELLCOME FOUNDATION LTD., "Quaternary Ammonium Compounds"; & GB,A,982 572. * |
CHEN ET AL.: "diltiazem and its analog, TA-3090", J. BONE AND MINERAL RES., vol. 5, 1990, pages 581 |
HETEROCYCLES, 35(1), (1977), TAKANO et al., "A Facile Route to Tetrahydroisoquinoline Alkaloids via Sulfoxide Mediated Cyclization", p. 47-52. * |
J. PHARM. SCI., 65(4), (1976), RILEY et al., "Synthesis and alpha-Adrenolytic Activity of Chiral N-Aralkyl-beta-Haloethylamines", p. 544-547. * |
ZAIDI ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 167, 1990, pages 807 |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713473B1 (en) | 1999-04-20 | 2004-03-30 | Meiji Seika Kaisha, Ltd. | Tricyclic compounds |
US6967216B2 (en) | 2000-05-05 | 2005-11-22 | Astrazeneca Ab | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor |
US7332492B2 (en) | 2000-05-05 | 2008-02-19 | Astrazeneca Ab | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor |
US7408064B2 (en) | 2001-09-11 | 2008-08-05 | Astrazeneca Ab | Carbazole derivatives and their use as NPY5 receptor antagonists |
US6908935B2 (en) | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
US7176322B2 (en) | 2002-05-23 | 2007-02-13 | Amgen Inc. | Calcium receptor modulating agents |
US7196102B2 (en) | 2002-05-23 | 2007-03-27 | Amgen Inc. | Calcium receptor modulating agents |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
EP2127654A1 (en) * | 2004-03-25 | 2009-12-02 | The Trustees of Columbia University in the City of New York | Benzothiazepine derivatives as ryanodine receptor (RYR2) inhibitors and their use in the treatment of cardiac diseases |
US8492111B2 (en) | 2004-05-28 | 2013-07-23 | Mitsubishi Tanabe Pharma Corporation | Arylalkylamine compound and process for preparing the same |
US8362274B2 (en) | 2004-05-28 | 2013-01-29 | Mitsubishi Tanabe Pharma Corporation | Arylalkylamine compound and process for preparing the same |
US8778628B2 (en) | 2004-05-28 | 2014-07-15 | Mitsubishi Tanabe Pharma Corporation | Arylalkylamine compound and process for preparing the same |
US8759387B2 (en) | 2004-05-28 | 2014-06-24 | Mitsubishi Tanabe Pharma Corporation | Arylalkylamine compound and process for preparing the same |
US8703721B2 (en) | 2004-05-28 | 2014-04-22 | Mitsubishi Tanabe Pharma Corporation | Arylalkylamine compound and process for preparing the same |
US7361789B1 (en) | 2004-07-28 | 2008-04-22 | Amgen Inc. | Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis |
JP2009507017A (ja) * | 2005-09-02 | 2009-02-19 | アムジエン・インコーポレーテツド | 腸液バランスを調節する方法 |
US8486381B2 (en) | 2005-09-02 | 2013-07-16 | Amgen Inc. | Methods of modulating intestinal fluid balance |
US8765676B2 (en) | 2009-05-27 | 2014-07-01 | Leo Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
WO2010136035A2 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
WO2010136037A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
US8785494B2 (en) | 2009-05-27 | 2014-07-22 | Leo-Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
WO2010150837A1 (ja) * | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
WO2012000499A1 (en) | 2010-06-30 | 2012-01-05 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
WO2012000498A1 (en) | 2010-06-30 | 2012-01-05 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
US8946474B2 (en) | 2010-06-30 | 2015-02-03 | Leo Pharma A/S | Polymorphic form of a calcimimetic compound |
US9056814B2 (en) | 2010-06-30 | 2015-06-16 | Leo Pharma A/S | Polymorphic form of a calcimimetic compound |
WO2012069421A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
WO2012069420A2 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
WO2012069402A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Substituted cyclopentyl - azines as casr- active compounds |
WO2012069419A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
Also Published As
Publication number | Publication date |
---|---|
US7816408B2 (en) | 2010-10-19 |
US6750255B2 (en) | 2004-06-15 |
EP0933354A1 (en) | 1999-08-04 |
JP4140859B2 (ja) | 2008-08-27 |
KR20000023645A (ko) | 2000-04-25 |
US20090176993A1 (en) | 2009-07-09 |
US20030144526A1 (en) | 2003-07-31 |
DE69740158D1 (de) | 2011-05-12 |
US20020107406A1 (en) | 2002-08-08 |
JP2007153904A (ja) | 2007-06-21 |
CA2259922A1 (en) | 1998-01-15 |
JP4331264B2 (ja) | 2009-09-16 |
US6362231B1 (en) | 2002-03-26 |
HK1020942A1 (en) | 2000-05-26 |
ATE503739T1 (de) | 2011-04-15 |
ES2364179T3 (es) | 2011-08-26 |
US20030176485A1 (en) | 2003-09-18 |
EP0933354A4 (en) | 2004-09-29 |
US6939895B2 (en) | 2005-09-06 |
AU3359797A (en) | 1998-02-02 |
AU734710B2 (en) | 2001-06-21 |
CA2259922C (en) | 2009-04-28 |
KR100771092B1 (ko) | 2007-10-30 |
KR20060135969A (ko) | 2006-12-29 |
EP0933354B1 (en) | 2011-03-30 |
TW510896B (en) | 2002-11-21 |
KR100860655B1 (ko) | 2008-09-26 |
CN1225083A (zh) | 1999-08-04 |
CN1131202C (zh) | 2003-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998001417A1 (fr) | Composes actifs comme recepteurs du calcium | |
FI120256B (fi) | Menetelmä uusien terapeuttisesti aktiivisten 3,3-difenyylipropyyliamiinien valmistamiseksi ja välituotteita | |
FI105477B (fi) | 1-[(4-kloorifenyyli)fenyylimetyyli]-4-[(4-metyylifenyyli)sulfonyyli]piperatsiinin enantiomeerit ja menetelmä niiden valmistamiseksi | |
CN109438298B (zh) | 作为有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物 | |
US5637583A (en) | Aminocyclohexylesters and uses thereof | |
DK169071B1 (da) | Benzacetamidderivater, fremgangsmåder til deres fremstilling samt et farmaceutisk præparat indeholdende et sådant derivat | |
BRPI0611966B1 (pt) | Composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo | |
RU2138479C1 (ru) | Производные n-(3-аминопропил)-n-фенил-5,6,7,8-тетрагидронафталин-2-карбоксамида, способ их получения и фармацевтическая композиция | |
US2541211A (en) | Tertiary-aminoalkyl-tetrahydrocarbazoles | |
CN101516826A (zh) | β-3受体配体及其治疗用途 | |
CN110372571B (zh) | 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物 | |
AU7558501A (en) | Calcium receptor active compounds | |
MXPA99000453A (en) | Active compounds receivers of cal | |
JP2003519115A (ja) | 置換1−および2−ナフトールマンニッヒ塩基 | |
NO862494L (no) | Fremgangsmaate for fremstilling av nye aromatiske forbindelser. | |
JPH0465067B2 (ja) | ||
SU1634135A3 (ru) | Способ получени аминопропанольных производных 3-(2-оксифенил)-1-пропанона или их фармакологически приемлемых солей | |
NO845031L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-(1-imidazolyl)-etanol-derivater | |
CN110981786A (zh) | 2-芳乙烯基-环胺衍生物及其制备方法和应用 | |
IE883785L (en) | 5-n-methylamino-3-heptanone derivative | |
WO2011011277A1 (en) | Inhibitor(s) of transporters or uptake of monoaminergic neurotransmitters | |
PT85976B (de) | Verfahren zur herstellung von (<)-1-isopropylamino-3-]o-(pyrrol-1-yl)-phenoxy"-2-propanol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97196285.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU IL IS JP KE KG KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2259922 Country of ref document: CA Ref document number: 2259922 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09214552 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/000453 Country of ref document: MX Ref document number: 1019997000098 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997929555 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997929555 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997000098 Country of ref document: KR |